

CITATION REPORT

List of articles citing

Role of diabetes in congestive heart failure: the Framingham study

DOI: 10.1016/0002-9149(74)90089-7

American Journal of Cardiology, 1974, 34, 29-34.

Source: <https://exaly.com/paper-pdf/11892834/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1664	Chronic diabetes followed by chronic cerebral ischemia induced by bilateral carotid artery ligation in arteriosclerotic versus nonarteriosclerotic rats. 1975 , 6, 432-4		8
1663	Letter: Myocardial infarction and control of diabetic metabolism. 1976 , 2, 180		
1662	Recent highlights from the Framingham study. 1976 , 6, 373-86		33
1661	A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. 1976 , 25, 1129-53		118
1660	Cardiomyopathic syndrome due to coronary arter disease. II: Increased prevalence in patients with diabetes mellitus: a matched pair analysis. 1977 , 39, 740-7		35
1659	Preventive cardiology. What should the clinician be doing about it?. 1977 , 61, 74-85		9
1658	Diabetic cardiomyopathy: the preclinical phase. 1977 , 1, 1444-6		94
1657	The heart in diabetes: autonomic neuropathy and cardiomyopathy. 1977 , 6, 377-88		77
1656	Diabetes and the heart: coronary heart disease. 1977 , 6, 389-402		25
1655	Status of coronary heart disease risk factors. 1978 , 10, 10-14		11
1654	Noninvasive estimation of myocardial performance in patients with diabetes. Effect of alcohol administration. 1978 , 27, 127-34		71
1653	Asymptomatic coronary artery disease: angiographic assessment of diabetics evaluated for renal transplantation. 1978 , 58, 1184-90		70
1652	Capillary basal laminar thichness in diabetic human myocardium. 1979 , 28, 713-9		98
1651	Cardiomyopathic syndrome caused by coronary artery disease. III: Prospective clinicopathological study of its prevalence among patients with clinically unexplained chronic heart failure. 1979 , 41, 613-20		17
1650	Diabetes and Cardiovascular Disease. 1979 , 241, 2035		2245
1649	Hereditary and acquired cardiomyopathies in experimental animals: mechanical, biochemical, and structural features. 1979 , 317, 59-88		93
1648	Preoperative endocrine and metabolic considerations. 1979 , 63, 1321-34		14

1647	Role of risk factors in complications of diabetes mellitus. 1980 , 112, 100-12	70
1646	The effect of diabetes on performance and metabolism of rat hearts. 1980 , 47, 911-21	237
1645	Altered myocardial mechanics in diabetic rats. 1980 , 47, 922-33	324
1644	Severity of coronary artery disease in patients with diabetes mellitus. Angiographic study of 34 diabetic and 120 nondiabetic patients. 1980 , 100, 782-7	61
1643	Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. 1980 , 99, 446-58	204
1642	Primary myocardial disease. Correlation with clinical findings, angiographic and biopsy diagnosis. Follow-up of 139 patients. 1980 , 99, 198-207	85
1641	Exercise testing with myocardial scintigraphy in asymptomatic diabetic males. 1981 , 63, 54-64	86
1640	Hyperglycemia and arterial disease. 1981 , 30, 49-53	41
1639	Blood glucose and atherosclerosis. 1981 , 1, 227-34	40
1638	Reversibility of diabetic cardiomyopathy with insulin in rats. 1981 , 49, 1251-61	179
1637	The hypertensions of diabetes. <i>Diabetes Care</i> , 1982 , 5, 50-8	14.6 52
1636	Treating hypertension in the patient with diabetes mellitus. 1982 , 66, 1373-88	14
1635	[Diabetic cardiomyopathy: clinical, hemodynamic and histopathologic as]ects. Case report]. 1982 , 3, 197-204	1
1634	Diabetes and the heart. <i>American Journal of Cardiology</i> , 1982 , 49, 2043-4	3
1633	Coronary artery disease in diabetic and nondiabetic patients: a clinical and angiographic comparison. 1983 , 6, 440-6	27
1632	Preclinical abnormality of left ventricular performance in patients with insulin-dependent diabetes mellitus. 1983 , 20, 311-20	15
1631	Hypertensive diabetic cardiomyopathy in the rat: ultrastructural features. 1983 , 398, 305-17	32
1630	Chronic diabetes decreases the ouabain inotropic response in rat left atria and papillary muscles. 1983 , 14, 401-5	7

1629	Altered myocardial response to ouabain in diabetic rats: mechanics and electrophysiology. 1983 , 15, 769-84	52
1628	Diabetic cardiomyopathy in rats: mechanical and biochemical response to different insulin doses. 1984 , 247, H817-23	12
1627	Nonenzymatic glycosylation of proteins--a new tool for assessment of cumulative hyperglycemia in epidemiologic studies, past and future. 1984 , 120, 169-89	28
1626	The Memphis and Atlanta continuing care programs for diabetes. II. Comparative analyses of demographic characteristics, treatment methods, and outcomes over a 9-10-year follow-up period. <i>Diabetes Care</i> , 1984 , 7, 25-31	14.6 59
1625	Combined renovascular hypertension and diabetes in rats: a new preparation of congestive cardiomyopathy. 1984 , 70, 318-30	61
1624	Risk factor analysis. 1984 , 26, 309-32	62
1623	Evaluation of myocardial function in cardiomyopathic states. 1984 , 27, 115-32	28
1622	Decrease in ventricular beta-adrenergic receptors in trained diabetic rats. 1984 , 79, 432-9	9
1621	Clinically unrecognized ventricular dysfunction in young diabetic patients. 1984 , 4, 234-8	113
1620	An epidemiological perspective of sudden death. 26-year follow-up in the Framingham Study. 1984 , 28 Suppl 1, 1-16	49
1619	Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. 1984 , 108, 31-7	214
1618	Pathomorphologic aspects of muscular tissue in diabetes mellitus. 1984 , 15, 1127-36	73
1617	Depression of calcium transport in sarcoplasmic reticulum from diabetic rats: lack of involvement by specific regulatory mediators. 1984 , 15, 1-5	10
1616	Diabetic nephropathy. 1984 , 31, 635-51	2
1615	Juvenile diabetes and the heart. 1984 , 31, 653-63	3
1614	Diabetic cardiomyopathy: the available evidence. 1985 , 30, 83-8	1
1613	Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged, newly diagnosed type 2 (non-insulin-dependent) diabetic subjects. 1985 , 28, 22-7	167
1612	Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetes Drafting Group. 1985 , 28 Suppl, 615-40	320

1611	The significance of repeated exercise testing with thallium-201 scanning in asymptomatic diabetic males. 1985 , 8, 621-8		11
1610	Diabetic cardiomyopathy. 1985 , 27, 255-70		246
1609	Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. 1985 , 1, 43-7		85
1608	Altered myocardial mechanics in diabetic rabbits. 1985 , 248, H729-36		10
1607	Insulin-dependent diabetes mellitus and ischemic heart disease. <i>Diabetes Care</i> , 1985 , 8 Suppl 1, 65-70	14.6	36
1606	[Existence of asymptomatic changes in left ventricular function in the diabetic. Noninvasive study]. 1985 , 6, 68-76		4
1605	Defective energy metabolism of the heart in diabetes. 1985 , 1, 139-41		46
1604	Epidemiology of congestive heart failure. <i>American Journal of Cardiology</i> , 1985 , 55, 3A-8A	3	241
1603	Relation of hemoglobin A1 and blood glucose to cardiac function in diabetes mellitus. <i>American Journal of Cardiology</i> , 1985 , 56, 642-6	3	30
1602	Psychosocial and other features of coronary heart disease: insights from the Framingham Study. 1986 , 112, 1066-73		27
1601	Abnormal cardiovascular response to exercise in young asymptomatic diabetic patients with retinopathy. 1986 , 112, 554-60		36
1600	Obesity and nutrition in elderly diabetic patients. 1986 , 80, 22-30		17
1599	Diabetes-induced abnormalities in the myocardium. 1986 , 38, 959-74		91
1598	Radionuclide assessment of left ventricular diastolic filling in diabetes mellitus with and without cardiac autonomic neuropathy. 1986 , 7, 1303-9		120
1597	Acebutolol in the treatment of diabetic patients with hypertension. 1986 , 10, 122-7		3
1596	Diabetes-induced cardiac changes. 1986 , 7, 364-367		19
1595	Adverse Effects of Antihypertensive Drug Therapy on Glucose Intolerance. 1986 , 4, 117-135		28
1594	Risk of hypothermia in elderly patients with diabetes. 1986 , 293, 416-8		34

1593	Chronic effects of streptozotocin diabetes on myocardial sensitivity in the rat. 1986 , 29, 741-8		24
1592	Congestive heart failure. 1986 , 11, 301-65		3
1591	Increase in atrial contractility induced by PGE2 in diabetic rats. 1986 , 18, 371-84		5
1590	Clinical studies on diabetic myocardial disease using exercise testing with myocardial scintigraphy and endomyocardial biopsy. 1986 , 9, 375-82		43
1589	Epidemiology and prevention of cardiac failure: Framingham Study insights. 1987 , 8 Suppl F, 23-6		110
1588	Exercise Thallium Imaging in Patients With Diabetes Mellitus. 1987 , 147, 313		32
1587	Primary prevention of diabetes mellitus. <i>Diabetes Care</i> , 1987 , 10, 238-48	14.6	45
1586	Congestive heart failure. What has long-term medical treatment to offer and what does it cost?. 1987 , 8 Suppl F, 26-8		4
1585	Metabolic and morphological changes of the heart in Chinese hamsters (CHAD strain) with spontaneous long-term diabetes. 1987 , 3, 297-305		16
1584	Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. 1987 , 82, 1119-26		28
1583	Atherosclerosis risk factors. 1987 , 32, 207-35		27
1582	Alterations in heart and serum lysosomal activities in streptozotocin-induced diabetes. 1987 , 82, 271-8		6
1581	Synergistic effects of diabetes mellitus and renovascular hypertension on the rat heart--stereological investigations on papillary muscles. 1987 , 411, 531-42		14
1580	Diabetes and atherosclerosis: an epidemiologic view. 1987 , 3, 463-524		681
1579	Status of risk factors and their consideration in antihypertensive therapy. <i>American Journal of Cardiology</i> , 1987 , 59, 80A-90A	3	44
1578	Predictive value of clinical and exercise variables for detection of coronary artery disease in men with diabetes mellitus. <i>American Journal of Cardiology</i> , 1987 , 59, 1310-3	3	43
1577	Frequency of painless myocardial ischemia during exercise tolerance testing in patients with and without diabetes mellitus. <i>American Journal of Cardiology</i> , 1987 , 59, 61-5	3	75
1576	Structural manifestations of diabetic cardiomyopathy in the rat and its reversal by insulin treatment. 1988 , 182, 270-82		58

1575	Epidemiology and risk profile of cardiac failure. 1988 , 2, 387-395		32
1574	Impairment of diastolic function in middle-aged type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients free of cardiovascular disease. 1988 , 31, 783-91		58
1573	Diabetic cardiopathy: is it a real entity?. 1988 , 4, 273-88		26
1572	Impaired left ventricular systolic function during exercise in middle-aged insulin-dependent and noninsulin-dependent diabetic subjects without clinically evident cardiovascular disease. <i>American Journal of Cardiology</i> , 1988 , 62, 1273-9	3	59
1571	Systemic hypertension in diabetes mellitus. <i>American Journal of Cardiology</i> , 1988 , 61, 34H-40H	3	15
1570	Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. <i>American Journal of Cardiology</i> , 1988 , 62, 665-9	3	111
1569	The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. 1988 , 115, 640-56		49
1568	Mitochondrial creatine phosphokinase deficiency in diabetic rat heart. 1988 , 154, 469-75		32
1567	Congestive heart failure. 1988 , 34, 465-536		10
1566	Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. 1988 , 12, 114-20		203
1565	Cardiomyopathy in childhood diabetes mellitus: incidence, time of onset, and relation to metabolic control. 1988 , 19, 225-36		29
1564	Asymptomatic diabetic cardiomyopathy: a noninvasive study. 1988 , 4, 183-90		36
1563	Diabetes mellitus and arteriographically-documented coronary artery disease. 1988 , 41, 659-68		25
1562	Deficiency of cardiac beta-adrenergic receptor in streptozocin-induced diabetic rats. 1988 , 37, 1181-7		66
1561	Subclinical left ventricular abnormalities in young diabetics. 1988 , 93, 1031-4		32
1560	Effect of myo-inositol and T3 on myocardial lipids and cardiac function in streptozocin-induced diabetic rats. 1988 , 37, 1542-8		21
1559	Adenine nucleotide metabolism in hearts of diabetic rats. Comparison to diaphragm, liver, and kidney. 1988 , 37, 629-36		21
1558	Glycosylation and cross-linkage of cardiac myosin in diabetic subjects: a post-mortem study. 1988 , 5, 338-42		12

1557	Hypertension and diabetes. 1988 , 72, 1399-414		50
1556	Literatur. 1988 , 121-156		
1555	The Dilated Cardiomyopathies: Experimental Aspects. 1988 , 6, 219-231		2
1554	Epidemiological Aspects of Heart Failure. 1989 , 7, 1-9		102
1553	Exercise testing, clinical, and angiographic characteristics of anginal patients with and without diabetes mellitus. 1989 , 40, 656-65		4
1552	Improving the detection and diagnosis of congestive heart failure. 1989 , 10 Suppl C, 13-8		33
1551	Diabetic heart disease: the clinical and pathological spectrum--Part I. 1989 , 12, 600-4		13
1550	Prevalence and significance of left ventricular filling abnormalities determined by Doppler echocardiography in young type I (insulin-dependent) diabetic patients. <i>American Journal of Cardiology</i> , 1989 , 64, 1010-6	3	100
1549	[Stress testing of long-term type I diabetic patients with radionuclide ventriculography]. 1989 , 67, 496-501		2
1548	Coronary blood flow in chronic insulin-dependent diabetic dogs. 1989 , 26, 275-82		1
1547	Endomyocardial biopsy pathology in insulin-dependent diabetic patients with abnormal ventricular function. 1989 , 14, 593-602		45
1546	Diabetic myocardial infarction. Interaction of diabetes with other preinfarction risk factors. 1989 , 38, 350-7		107
1545	Diabetic cardiomyopathy. 1989 , 118, 1000-12		203
1544	Myocardial disease in hypertensive-diabetic patients. 1989 , 87, 235-285		23
1543	Autonomic influence on cardiovascular performance in diabetic subjects. 1989 , 87, 382-8		90
1542	The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. 1989 , 14, 49-57		426
1541	Alterations in atrial reactivity in a strain of spontaneously diabetic rats. 1989 , 97, 1137-44		16
1540	Effect of age and methacholine on the rate and coronary flow of isolated hearts of diabetic rats. 1989 , 97, 1209-17		19

1539	Autonomic dysfunction and silent myocardial ischaemia on exercise testing in diabetes mellitus. 1990 , 7, 580-4	53
1538	Evidence for a specific heart disease of diabetes in humans. 1990 , 7, 478-89	23
1537	Diabetes mellitus and silent myocardial ischemia. 1990 , 37, 297-303	5
1536	Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease. 1990 , 258, E606-18	44
1535	Cardiopathy in Type 1 Diabetic Subjects: A Review with Emphasis on Noninvasive Studies. 1990 , 4, 246-253	2
1534	Congestive heart failure in women: focus on heart failure due to coronary artery disease and diabetes. 1990 , 77 Suppl 2, 71-9	28
1533	Clinical implications of hypertension in the diabetic patient. 1990 , 3, 415-24	41
1532	Increase in [3H]PN 200-110 binding to cardiac muscle membrane in streptozocin-induced diabetic rats. 1990 , 39, 1064-9	24
1531	Diabetic heart muscle disease. 1990 , 22, 377-86	62
1530	Thyroid hormones mediated effect of insulin on alloxan diabetic rat atria. 1990 , 21, 735-40	29
1529	Effects of chronic non-ketotic diabetes and aging on myocardial function and fatty acid oxidation. 1990 , 4, 26-34	2
1528	Does a clinically definable diabetic cardiomyopathy exist?. 1990 , 15, 1518-20	12
1527	Evidence against the involvement of nonenzymatic glycosylation in diabetic cardiomyopathy. 1990 , 39, 769-73	13
1526	Altered functional activity and anoxic tolerance in diabetic rat isolated atria. 1990 , 279, 183-7	9
1525	Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. 1990 , 120, 672-6	292
1524	Prolonged anginal perceptual threshold in diabetes: effects on exercise capacity and myocardial ischemia. 1990 , 16, 1120-4	25
1523	Correlation between histopathological changes and mechanical dysfunction in diabetic rat hearts. 1991 , 11, 177-88	21
1522	The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. 1991 , 20, 477-90	109

1521	Beneficial effects of diltiazem on the natural history of hypertensive diabetic cardiomyopathy in rats. 1991 , 18, 1406-17		18
1520	The effects of streptozotocin induced diabetes mellitus and fish oil compound on gene expression of atrial natriuretic peptide in rat. 1991 , 100, 221-5		4
1519	Diastolic ventricular function in type 1 diabetic patients: a study using Doppler echocardiography. 1991 , 8, 208-12		11
1518	Myocardial metabolism in type 1 diabetic patients without coronary artery disease. 1991 , 8 Spec No, S104-7		25
1517	Cardiac function and exercise capacity of diabetic patients. 1991 , 37 Suppl, S25-33		
1516	Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). <i>American Journal of Cardiology</i> , 1991 , 68, 85-9	3	429
1515	Detection of silent myocardial ischemia in diabetes mellitus. <i>American Journal of Cardiology</i> , 1991 , 67, 1073-8	3	149
1514	Left ventricular function and wall thickness in long-term insulin-dependent diabetes mellitus: an echocardiographic study. 1991 , 229, 527-31		9
1513	The management of congestive heart failure in diabetes mellitus. 1991 , 8, 18-21		
1512	Cardiovascular sequelae of endotoxin shock in diabetic dogs. 1991 , 34, 687-94		4
1511	Demonstration of disturbed free fatty acid metabolism of myocardium in patients with non-insulin-dependent diabetes mellitus as measured with iodine-123-heptadecanoic acid. 1991 , 18, 475-81		7
1510	Left Ventricular Mass in Diabetes-Hypertension. 1992 , 152, 1001		63
1509	Clinical review 36: Cardiovascular manifestations of endocrine disease. 1992 , 75, 339-42		35
1508	Impaired circadian modulation of sympathovagal activity in diabetes. A possible explanation for altered temporal onset of cardiovascular disease. 1992 , 86, 1443-52		212
1507	Cardiac Dysfunction in Chronic Uremia. 1992 ,		0
1506	Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. 1992 , 85, 1254-64		192
1505	Diabetic type of cardiomyopathy in food-restricted rats. 1992 , 70, 1040-7		13
1504	Ultrasound tissue characterization of the diabetic heart: laboratory curiosity or clinical tool?. 1992 , 19, 1163-4		6

- 1503 Lessons From Framingham: Cardiac Disease in the General Population. **1992**, 19-38
- 1502 Acute insulin withdrawal from diabetic BB rats decreases myocardial glycolysis during low-flow ischemia. **1992**, 41, 332-8 14
- 1501 Cytosolic Ca²⁺ concentration and pH of diabetic rat myocytes during metabolic inhibition. **1992**, 24, 435-46 22
- 1500 Scintigraphic evaluation of left ventricular function and correlation with autonomic cardiac neuropathy in diabetic patients. **1992**, 81, 14-24 8
- 1499 Anatomical and functional cardiac abnormalities in type I diabetes. **1992**, 70, 403-10 9
- 1498 Effects of combined renovascular hypertension and diabetes mellitus on myocardial cells, non-vascular interstitium and capillaries: a stereological study on rat hearts. **1992**, 420, 499-506 9
- 1497 Influence of diltiazem and/or propranolol on rat blood glucose levels in normal and diabetic animals. **1993**, 13, 85-9 3
- 1496 The effects of glyburide and insulin on the cardiac performance in rats with non-insulin-dependent diabetes mellitus. **1993**, 24, 165-9 14
- 1495 Observations on atrial natriuretic peptide, sympathetic activity and renal Ca²⁺ pump in diabetic and hypertensive rats. **1993**, 3, 137-43 6
- 1494 Spectrum and outcome of congestive heart failure in a hospitalized population. **1993**, 126, 632-40 92
- 1493 Inotropic effects of ethanol on the isolated papillary muscle of the diabetic rat. **1993**, 10, 231-5 11
- 1492 Comparison of cardiac morbidity rates between aortic and infrainguinal operations: Two-year follow-up. **1993**, 18, 609-617 61
- 1491 Increased capillary permeability to albumin in diabetic rat myocardium. **1993**, 72, 947-57 39
- 1490 Association of diabetes mellitus with coronary atherosclerosis and myocardial lesions. An autopsy study from the Honolulu Heart Program. **1993**, 137, 1328-40 65
- 1489 Left ventricular diastolic filling properties in diabetic patients during isometric exercise. **1993**, 83, 316-23 23
- 1488 Increased Myocardial Contractility in Young Newly Diagnosed Type 1 (Insulin-Dependent) Diabetics Free of Diabetic Complications: An Echocardiographic Study. **1993**, 7, 57-62 2
- 1487 The Cohen diabetic (non-insulin-dependent) hypertensive rat model. Description of the model and pathologic findings. **1993**, 6, 989-95 30
- 1486 Prevalence and Prognosis of Heart Failure. **1994**, 12, 1-8 11

1485	Early Diabetic Nephropathy. 1994 , 154, 625		5
1484	Role of glucose intolerance in cardiac diastolic function in essential hypertension. 1994 , 23, 1002-5		30
1483	Left ventricular function and specific diabetic complications in other target organs in young insulin-dependent diabetics: an echocardiographic study. 1994 , 9, 121-8		17
1482	Diabetic cardiomyopathy. 1994 , 8, 65-73		103
1481	Increased alpha 1-adrenergic responsiveness of alloxan diabetic rat atria: effects of insulin therapy and thyroidectomy. 1994 , 25, 559-64		11
1480	Resting parasympathetic status and cardiovascular response to orthostatic and behavioral challenges in type I insulin-dependent diabetes mellitus. 1994 , 1, 137-62		2
1479	Left ventricular systolic function in middle-aged patients with diabetes mellitus. <i>American Journal of Cardiology</i> , 1994 , 73, 1202-8	3	39
1478	Changes in the responsiveness to endothelin-1 in isolated atria from diabetic rats. 1994 , 261, 33-42		11
1477	Congestive heart failure in mitochondrial diabetes mellitus. 1994 , 344, 1375		18
1476	Diabetes mellitus and risk of idiopathic dilated cardiomyopathy. The Washington, DC Dilated Cardiomyopathy Study. 1994 , 4, 67-74		58
1475	Preservation of Left Ventricular function and Coronary Flow by Angiotensin I-Converting Enzyme Inhibition in the Hypertensive-Diabetic Dahl Rat. 1994 , 7, 919-925		14
1474	Glucose intolerance exaggerates left ventricular hypertrophy and dysfunction in essential hypertension. 1994 , 7, 1110-4		25
1473	Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. 1994 , 151, 54-61		3818
1472	Assessment of cardiovascular risk factors in the elderly: the Framingham Heart Study. 1995 , 14, 1745-56		28
1471	Integrated analysis of erythrocyte Na ⁺ /H ⁺ antiport activity and left ventricular myocardial function in type I insulin-dependent diabetes mellitus. 1995 , 9, 208-11		4
1470	Myocardial dysfunction and abnormal left ventricular exercise response in autonomic diabetic patients. 1995 , 18, 276-82		15
1469	Effects of type 1 diabetes mellitus on cardiac function: a study of monozygotic twins. 1995 , 73, 450-5		21
1468	Increased echodensity of myocardial wall in the diabetic heart: an ultrasound tissue characterization study. 1995 , 25, 1408-15		97

1467	Antihypertensive and Metabolic Effects of Amlodipine in Patients with Non-Insulin-Dependent Diabetes Mellitus. 1995 , 9, 16-21		3
1466	Heart disease in diabetes mellitus. 1996 , 25, 425-38		29
1465	Is diabetic heart muscle disease related to cardiac ischemia or autonomic neuropathy?. 1996 , 30 Suppl, 77-83		
1464	Functional responses of the left and right heart of diabetic rats to alpha- and beta-adrenergic receptor stimulation. 1996 , 31 Suppl, S79-86		15
1463	Diabetic cardiomyopathy in rats: alleviation of myocardial dysfunction caused by Ca ²⁺ overload. 1996 , 31 Suppl, S105-12		21
1462	Myocardial alterations in diabetes and hypertension. 1996 , 31 Suppl, S133-42		30
1461	The Progression From Hypertension to Congestive Heart Failure. 1996 , 275, 1557		1137
1460	Diabetic and hypertensive heart disease. 1996 , 125, 304-10		116
1459	Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. 1996 , 124, 123-6		68
1458	The appearance of gallop rhythm after exercise stress testing. 1996 , 19, 887-91		7
1457	Correlation between myocardial dysfunction and changes in myosin isoenzymes in diabetic rat hearts. 1996 , 10, 38-42		3
1456	Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. <i>American Journal of Cardiology</i> , 1996 , 77, 1017-20	3	362
1455	Left ventricular performance and autonomic dysfunction in patients with long-term insulin-dependent diabetes mellitus. 1996 , 33, 269-73		11
1454	Prolonged ejection duration helps to maintain pump performance of the renal-hypertensive-diabetic rat heart: correlations between isolated papillary muscle function and ventricular performance in situ. 1997 , 34, 230-40		11
1453	Changes in electrophysiological and mechanical responses of the rat papillary muscle to β -agonist in streptozotocin-induced diabetes. 1997 , 75, 781-788		15
1452	Fructose-3-phosphate production and polyol pathway metabolism in diabetic rat hearts. 1997 , 46, 1333-8		28
1451	Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. 1997 , 17, 2250-6		77
1450	The prediabetic problem: development of non-insulin-dependent diabetes mellitus and related abnormalities. 1997 , 11, 69-76		18

1449	Isolated and preclinical impairment of left ventricular filling in insulin-dependent and non-insulin-dependent diabetic patients. 1997 , 20, 536-40	46
1448	A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. 1997 , 12, 267-74	92
1447	Erythrocyte Na ⁺ /H ⁺ exchange and preclinical abnormalities of the left ventricular diastolic function in normotensive type 1 (insulin-dependent) diabetic patients. 1997 , 34, 223-9	4
1446	Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. 1997 , 40, 647-53	238
1445	Cardiac disease in diabetic end-stage renal disease. 1997 , 40, 1307-12	104
1444	Microvascular heart disease in diabetes mellitus. 1997 , 40 Suppl 2, S130-3	7
1443	Diabetic cardiomyopathy. 1998 , 21, 885-7	100
1442	Effects of propionyl-L-carnitine on cardiac dysfunction in streptozotocin-diabetic rats. 1998 , 357, 185-91	10
1441	Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. 1998 , 31, 404-12	96
1440	[Heart pathology of extracardiac origin. XI. Cardiac repercussions of diabetes mellitus]. 1998 , 51, 661-70	7
1439	Parasympathetic neuropathy associated with left ventricular diastolic dysfunction in patients with insulin-dependent diabetes mellitus. 1998 , 32, 17-22	21
1438	Drug administration in patients with diabetes mellitus. Safety considerations. 1998 , 18, 441-55	12
1437	Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. 1998 , 137 Suppl, S65-73	117
1436	[Anatomopathological bases of latent ventricular dysfunction in insulin-dependent diabetics]. 1998 , 51, 43-50	7
1435	Heart disease in diabetes mellitus: a challenge for early diagnosis and intervention. 1998 , 106, 16-24	18
1434	How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. 1998 , 19, 990-1003	552
1433	All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 45-74 years, 1984-1988. The Strong Heart Study. 1998 , 147, 995-1008	131
1432	Angiographic study of coronary artery disease in diabetic patients in comparison with nondiabetic patients. 1999 , 50, 997-1006	40

1431	Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. 1999 , 19, 1223-30		129
1430	The role of haematological factors in diabetic peripheral arterial disease: the Edinburgh artery study. 1999 , 105, 648-54		27
1429	Clinical characteristics of diabetic vs nondiabetic patients who "rule-in" for acute myocardial infarction. 1999 , 6, 719-23		15
1428	[Early decrease in diastolic function in young type I diabetic patients as an initial manifestation of diabetic cardiomyopathy]. 1999 , 88, 338-46		6
1427	Pharmaceutical care of patients with congestive heart failure: interventions and outcomes. 1999 , 19, 860-9		121
1426	Protective effects of Ginkgo biloba extract EGb 761 on myocardium of experimentally diabetic rats. I: ultrastructural and biochemical investigation on cardiomyocytes. 1999 , 51, 189-98		22
1425	Altered creatine kinase enzyme kinetics in diabetic cardiomyopathy. A(31)P NMR magnetization transfer study of the intact beating rat heart. 1999 , 31, 2175-89		36
1424	Diabetes and the heart. 1999 , 60, 90-4		
1423	Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. 1999 , 115, 867-8		111
1422	Evidence based cardiology: prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction. 1999 , 318, 1400-2		22
1421	Do diabetic patients have higher in-hospital complication rates when admitted from the emergency department for possible myocardial ischemia?. 2000 , 7, 264-8		2
1420	The influence of hypoxia on the myocardium of experimentally diabetic rats with and without protection by Ginkgo biloba extract. I. Ultrastructural and biochemical investigations on cardiomyocytes. 2000 , 52, 419-30		12
1419	Impaired glucose tolerance as a determinant of early deterioration of left ventricular diastolic function in middle-aged healthy subjects. <i>American Journal of Cardiology</i> , 2000 , 85, 790-2, A9	3	12
1418	Prognosis of aortic intramural hemorrhage compared with classic aortic dissection. <i>American Journal of Cardiology</i> , 2000 , 85, 792-5, A10	3	98
1417	Propionyl-L-carnitine effects on postischemic recovery of heart function and substrate oxidation in the diabetic rat. 2000 , 206, 151-7		14
1416	Coordinate regulation of metabolic enzyme encoding genes during cardiac development and following carvedilol therapy in spontaneously hypertensive rats. 2000 , 14, 31-9		23
1415	Is abnormal iodine-123-MIBG kinetics associated with left ventricular dysfunction in patients with diabetes mellitus?. 2000 , 7, 562-8		15
1414	Influence of autonomic neuropathy upon left ventricular dysfunction in insulin-dependent diabetic patients. 2000 , 23, 371-5		24

1413	Dietary supplementation of a natural isomer mixture of beta-carotene inhibits oxidation of LDL derived from patients with diabetes mellitus. 2000 , 44, 54-60	46
1412	Diminished expression of sarcoplasmic reticulum Ca(2+)-ATPase and ryanodine sensitive Ca(2+)Channel mRNA in streptozotocin-induced diabetic rat heart. 2000 , 32, 655-64	90
1411	Effects of acute hyperglycaemia on cardiac function: an echocardiographic study of monozygotic twins. 2000 , 74, 139-44	3
1410	The effects of glycation/glycooxidation on the liberation of 8-epi-PGF2alpha from low density lipoprotein during its in vitro oxidation. 2000 , 62, 217-24	3
1409	[Left ventricular diastolic dysfunction in young people with type 1 diabetes mellitus. Associated factors]. 2000 , 53, 603-10	0
1408	The health benefits of wine. 2000 , 20, 561-93	326
1407	Cardiomyopathy and heart failure in diabetes. 2001 , 30, 1031-46	16
1406	The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. 2001 , 37, 1943-9	257
1405	Blunted sympathetic response in diabetic patients with decompensated congestive heart failure. 2001 , 81, 243-9	9
1404	Transmural heterogeneity of myocardial integrated backscatter in diabetic patients without overt cardiac disease. 2001 , 52, 11-20	9
1403	Diabetes mellitus and coronary heart disease. 2001 , 30, 857-81	36
1402	The impact of heart failure on prognosis of diabetic and non-diabetic patients with myocardial infarction: a 15-year follow-up study. 2001 , 3, 83-90	19
1401	Serum HbA1c levels and exercise capacity in diabetic patients. 2001 , 42, 607-16	22
1400	Progression of functional and structural cardiac alterations in young normotensive uncomplicated patients with type 1 diabetes mellitus. 2001 , 19, 1675-80	38
1399	Metabolic cardiomyopathies. 2000 , 81, 349-72	83
1398	The effect of streptozotocin-induced diabetes on cardiac beta-adrenoceptor subtypes in the rat. 2001 , 21, 15-21	15
1397	Oxidative stress and diabetic cardiomyopathy: a brief review. 2001 , 1, 181-93	278
1396	[Prognostic factors of chronic heart insufficiency]. 2001 , 50, 21-9	

1395	Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation. 2001 , 61, 373-9		60
1394	Obesity in the pediatric patient: cardiovascular complications. 2001 , 12, 161-167		26
1393	A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. 2001 , 38, 992-1000		135
1392	Diabetes. 2001 , 59, 159-72		4
1391	A comparison of left ventricular abnormalities associated with glucose intolerance in African Caribbeans and Europeans in the UK. 2001 , 85, 643-8		12
1390	Early failure of the diabetic heart. <i>Diabetes Care</i> , 2001 , 24, 3-4	14.6	46
1389	Alteration of antioxidants during the progression of heart disease in streptozotocin-induced diabetic rats. 2001 , 34, 251-61		33
1388	Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. <i>Diabetes Care</i> , 2001 , 24, 5-10	14.6	564
1387	Glycemic control and heart failure among adult patients with diabetes. 2001 , 103, 2668-73		542
1386	Diabetic cardiomyopathy: fact or fiction?. 2001 , 85, 247-8		83
1385	Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. 2002 , 51, 1166-71		200
1384	Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. 2002 , 106, 1251-5		81
1383	Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group V: management of cardiovascular-renal complications. 2002 , 105, e159-64		22
1382	Overexpression of metallothionein reduces diabetic cardiomyopathy. 2002 , 51, 174-81		159
1381	Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. 2002 , 51, 2709-18		158
1380	Transgenic overexpression of the sarcoplasmic reticulum Ca ²⁺ ATPase improves reticular Ca ²⁺ handling in normal and diabetic rat hearts. 2002 , 16, 1657-9		79
1379	Regulatory networks controlling mitochondrial energy production in the developing, hypertrophied, and diabetic heart. 2002 , 67, 371-82		15
1378	Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats. 2002 , 283, H1398-408		199

1377	Pioglitazone Current profile. 2002 , 2, S18-S23		2
1376	Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. 2002 , 34, 1249-57		122
1375	Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. 2002 , 98, 33-9		214
1374	Peroxisome Proliferator-activated Receptor (PPAR) Signaling in the Gene Regulatory Control of Energy Metabolism in the Normal and Diseased Heart. 2002 , 34, 1249-1257		107
1373	Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. 2002 , 359, 1430-2		119
1372	[Prevention and treatment of congestive heart failure in diabetic patients]. 2002 , 55, 1083-7		3
1371	. 2002 ,		10
1370	Cardiac Complications and Management. 577-605		
1369	Streptozotocin diabetes protects against arrhythmias in rat isolated hearts: role of hypothyroidism. 2002 , 435, 269-76		27
1368	Status of glucose metabolism in patients with heart failure secondary to coronary artery disease. <i>American Journal of Cardiology</i> , 2002 , 90, 529-32	3	10
1367	The role of early hemodynamic impairment and disease duration on diabetic cardiomyopathy and hypertension in central Africans with atherosclerosis. 2002 , 16, 146-52		4
1366	Dilated cardiomyopathies as a cause of congestive heart failure. 2002 , 27, 113-34		21
1365	Left ventricular diastolic function is related to glucose in a middle-aged population. 2002 , 251, 415-20		30
1364	Non-invasive magnetic resonance imaging assessment of myocardial changes and the effects of angiotensin-converting enzyme inhibition in diabetic rats. 2002 , 538, 541-53		31
1363	Magnetic resonance imaging analysis of cardiac cycle events in diabetic rats: the effect of angiotensin-converting enzyme inhibition. 2002 , 538, 555-72		32
1362	Enhanced inhibition of L-type calcium currents by troglitazone in streptozotocin-induced diabetic rat cardiac ventricular myocytes. 2002 , 136, 803-10		11
1361	Myocardial Effects of Ethanol Consumption in the Rat With Streptozotocin-Induced Diabetes. 2002 , 26, 1128-1133		3
1360	Protective effect of selenium treatment on diabetes-induced myocardial structural alterations. 2002 , 89, 215-26		50

1359	Diabetic heart dysfunction: is cell transplantation a potential therapy?. 2003 , 8, 213-9	12
1358	Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. 2003 , 46, 760-5	515
1357	[Diabetic cardiopathy: pathogenesis, diagnosis and therapy]. 2003 , 44, 806-12, 814-8	3
1356	Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. 2003 , 23, 945-54	21
1355	The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. 2003 , 20, 607-21	60
1354	Preventing cardiovascular disease in diabetes and glucose intolerance: evidence and implications for care. 2003 , 30, 569-92	13
1353	Do thiazolidinediones cause congestive heart failure?. 2003 , 78, 1076-7	19
1352	Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. 2003 , 42, 328-35	289
1351	Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers. 2003 , 9, 192-202	42
1350	Heart failure in diabetic patients: utility of beta-blockade. 2003 , 9, 333-44	19
1349	Functional class in patients with heart failure is associated with the development of diabetes. 2003 , 114, 271-5	83
1348	Heme oxygenase in diabetes-induced oxidative stress in the heart. 2003 , 35, 1439-48	94
1347	A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. 2003 , 92, 785-92	363
1346	Demographics and concomitant disorders in heart failure. 2003 , 362, 147-58	118
1345	Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy?. 2003 , 29, 455-66	87
1344	Atherosclerosis, Hypertension and Diabetes. 2003 ,	2
1343	Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. <i>Diabetes Care</i> , 2003 , 26, 2791-5	163
1342	Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, Cardiovascular Events and Ramipril) study. <i>Diabetes Care</i> , 2003 , 26, 855-60	14.6 108

1341	Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. 2003 , 285, H2587-91		103
1340	Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. <i>Diabetes Care</i> , 2003 , 26, 2081-7	14.6	113
1339	Screening for treatable left ventricular abnormalities in diabetic patients. 2003 , 3, 107-12		4
1338	Myocardial metabolism: the diabetic heart. 2003 , 5, B15-B18		
1337	Diabetes, the renin-angiotensin system and heart disease. 2003 , 1, 225-38		3
1336	Trends in Management of Type 2 Diabetes. 2003 , 13, S1-S21		2
1335	Mechanisms in the pathogenesis of diabetic cardiomyopathy. 2003 , 10, 251-255		4
1334	Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis. 2003 , 100, 207-15		6
1333	Diabetes mellitus and coronary artery disease: therapeutic considerations. 2003 , 5, 119-28		4
1332	Impairment of Right Ventricular Diastolic Function in Early Type 2 Diabetes. 2003 , 33, 499		
1331	The epidemiology of heart failure. 2004 , 5 Suppl 1, S2-6		15
1330	Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. 2004 , 18, 828-35		81
1329	Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. 2004 , 164, 1737-48		81
1328	Effects of halothane on contraction and intracellular calcium in ventricular myocytes from streptozotocin-induced diabetic rats. 2004 , 92, 246-53		9
1327	Left ventricular remodeling and heart failure in diabetic patients treated with primary angioplasty for acute myocardial infarction. 2004 , 110, 1974-9		60
1326	The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea: an analysis from the Breathing Not Properly Multinational Study. <i>Diabetes Care</i> , 2004 , 27, 2398-404	14.6	19
1325	Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. <i>Diabetes Care</i> , 2004 , 27, 448-54	14.6	70
1324	Heart failure prevalence, incidence, and mortality in the elderly with diabetes. <i>Diabetes Care</i> , 2004 , 27, 699-703	14.6	395

1323	Management of chronic heart failure in the community: role of a hospital based open access heart failure service. 2004 , 90, 755-9		16
1322	Predictors of heart failure among women with coronary disease. 2004 , 110, 1424-30		126
1321	Altered inotropic reactivity in diabetic rabbit right ventricular myocardium. 2004 , 82, 903-10		3
1320	Left ventricular dysfunction in normotensive Type 1 diabetic patients: the impact of autonomic neuropathy. 2004 , 21, 524-30		43
1319	Thiazolidinediones and congestive heart failure--exacerbation or new onset of left ventricular dysfunction?. 2004 , 21, 945-50		18
1318	Protein kinase C modulation of the regulation of sarcoplasmic reticular function by protein kinase A-mediated phospholamban phosphorylation in diabetic rats. 2004 , 141, 347-59		5
1317	Early myocardial dysfunction in the diabetic heart: current research and clinical applications. <i>American Journal of Cardiology</i> , 2004 , 93, 17A-20A	3	23
1316	Effects of amino acid supplementation on left ventricular remodeling in patients with chronic heart failure with decreased systolic function and diabetes mellitus: rationale and design of a magnetic resonance imaging study. <i>American Journal of Cardiology</i> , 2004 , 93, 44A-46A	3	4
1315	Defective sarcolemmal phospholipase C signaling in diabetic cardiomyopathy. 2004 , 261, 193-9		22
1314	Linking gene expression to function: metabolic flexibility in the normal and diseased heart. 2004 , 1015, 202-13		182
1313	[Influence of impaired fasting glucose on the incidence and prognosis of atherosclerosis in various vascular regions]. 2004 , 93 Suppl 4, IV48-55		2
1312	Hopes, disillusion and more hopes from vitamin C. 2004 , 61, 209-19		60
1311	The ABC transporter structure and mechanism: perspectives on recent research. 2004 , 61, 682-99		406
1310	The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. 2004 , 61, 118-28		92
1309	Diabetes mellitus and cardiovascular disease. Pandora's box has been opened. 2004 , 29, 456-62		12
1308	[The impact of diabetes mellitus on the results of coronary artery bypass grafting with respect to left ventricular function]. 2004 , 29, 556-61		0
1307	Impaired glucose metabolism in patients with heart failure: pathophysiology and possible treatment strategies. 2004 , 4, 269-80		28
1306	The incidence of congestive heart failure in type 2 diabetes: an update. <i>Diabetes Care</i> , 2004 , 27, 1879-84	14.6	554

1305	Risk factors for heart failure. 2004 , 88, 1145-72	83
1304	Thiazolidinedione-associated congestive heart failure and pulmonary edema. 2004 , 79, 571-2; author reply 575-7	
1303	Ischemic heart disease and congestive heart failure in diabetic patients. 2004 , 88, 1037-61, xi-xii	18
1302	Heart failure in women. 2004 , 88, 1321-45, xii	63
1301	Preventing heart failure in patients with diabetes. 2004 , 88, 1237-56	10
1300	Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. 2004 , 43, 771-7	195
1299	Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. 2004 , 44, 1047-52	84
1298	Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. 2004 , 107, 539-57	250
1297	Combined thiazolidinedione-insulin therapy: should we be concerned about safety?. 2004 , 27, 841-56	48
1296	Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. 2004 , 6, 850-63	76
1295	The role of exercise in the treatment of cardiovascular disease associated with type 2 diabetes mellitus. 2004 , 34, 27-48	18
1294	Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. 2004 , 26, 1400-10	45
1293	Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl)lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. 2004 , 1636, 82-9	82
1292	Improved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitus. 2004 , 94, 47-51	31
1291	Approach to the management of diabetic patients with heart failure: role of thiazolidinediones. 2004 , 148, 551-8	17
1290	New insights into diastolic heart failure: role of diabetes mellitus. 2004 , 116 Suppl 5A, 64S-75S	65
1289	Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. 2004 , 13, 11-9	86
1288	Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. 2004 , 25, 543-67	711

1287	Latin American consensus on diabetes mellitus and hypertension. 2004 , 22, 2229-41		11
1286	Effects of sodium selenate treatment on altered responses of left and right atria from streptozotocin-induced diabetic rats. 2004 , 44, 9-15		3
1285	Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. 2004 , 44, 101-8		34
1284	Attenuated inhibition of L-type calcium currents by troglitazone in fructose-fed rat cardiac ventricular myocytes. 2004 , 44, 109-16		9
1283	Heart failure, diabetes and the thiazolidinediones: an unfolding story. 2005 , 2, 159-161		
1282	Insulin resistance and risk of congestive heart failure. 2005 , 294, 334-41		396
1281	Cardiomyocyte defects in diabetic models and protection with cardiac-targeted transgenes. 2005 , 112, 379-88		15
1280	Imaging of myocardial metabolism. 2005 , 12, 345-58		22
1279	Cardiomyocyte dysfunction in models of type 1 and type 2 diabetes. 2005 , 5, 285-92		41
1278	Overexpression of hexokinase protects hypoxic and diabetic cardiomyocytes by increasing ATP generation. 2005 , 5, 293-300		18
1277	Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. 2005 , 22, 1720-5		93
1276	Left ventricular function in patients with type 2 diabetes mellitus. <i>American Journal of Cardiology</i> , 2005 , 95, 798-801	3	9
1275	An approach to heart failure and diabetes mellitus. <i>American Journal of Cardiology</i> , 2005 , 96, 47E-52E	3	24
1274	Association of heart disease with diabetes and hypertension in patients with ESRD. 2005 , 45, 316-23		22
1273	Diastolic dysfunction and mortality in diabetic patients on hemodialysis: a 4.25-year controlled prospective study. 2005 , 19, 194-200		17
1272	Exercise training restores abnormal myocardial glucose utilization and cardiac function in diabetes. 2005 , 21, 44-50		47
1271	The incidence of congestive heart failure associated with antidiabetic therapies. 2005 , 21, 51-7		76
1270	Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. 2005 , 48, 1229-37		190

1269	Changes in crossbridge mechanical properties in diabetic rat cardiomyopathy. 2005 , 100, 231-9		12
1268	Lipotoxicity in the heart. 2005 , 7, 412-7		81
1267	Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. 2005 , 14, 697-703		20
1266	Exercise improves impaired ventricular function and alterations of cardiac myofibrillar proteins in diabetic dyslipidemic pigs. 2005 , 98, 461-7		24
1265	[Diastolic dysfunction in diabetic normotensive patients, regardless of the presence of microangiopathy]. 2005 , 84, 461-6		3
1264	Reversal of hyperglycemic preconditioning by angiotensin II: role of calcium transport. 2005 , 288, H1965-75		13
1263	Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. 2005 , 96, 225-33		352
1262	The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. 2005 , 54, 204-11		62
1261	Hyperglycemia activates JAK2 signaling pathway in human failing myocytes via angiotensin II-mediated oxidative stress. 2005 , 54, 394-401		50
1260	Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavík Study. 2005 , 12, 465-71		31
1259	Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. 2005 , 111, 2073-85		263
1258	Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. 2005 , 19, 2057-9		97
1257	Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. <i>Diabetes Care</i> , 2005 , 28, 20-6	14.6	71
1256	Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. <i>Diabetes Care</i> , 2005 , 28, 2345-51	14.6	310
1255	The association between glucose abnormalities and heart failure in the population-based Reykjavik study. <i>Diabetes Care</i> , 2005 , 28, 612-6	14.6	217
1254	Molecular defects in cardiac myofibrillar proteins due to thyroid hormone imbalance and diabetes. 2005 , 83, 1071-91		24
1253	Heart failure after myocardial revascularization: risk markers. 2005 , 105, 11-4		3
1252	Prevalence and characteristics of diabetic patients in a chronic heart failure population. 2005 , 100, 281-7		22

1251	Expression changes of thrombospondin-1 and neuropeptide Y in myocardium of STZ-induced rats. 2005 , 105, 192-7	26
1250	Normocytic normochromic anemia due to autonomic neuropathy in type 2 diabetic patients without severe nephropathy: a possible role of microangiopathy. 2005 , 70, 239-47	7
1249	Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. 2005 , 149, 168-74	147
1248	Left ventricular diastolic function in normotensive subjects 2 months after acute myocardial infarction is related to glucose intolerance. 2005 , 150, 168-74	4
1247	[Diabetes mellitus, heart failure and mortality]. 2005 , 125, 182-3	3
1246	Heart Failure and Cardiac Dysfunction in Diabetes. 2005 , 555-578	
1245	Diabetes Mellitus and Heart Disease. 2005 , 579-628	
1244	Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. 2005 , 46, 1019-26	210
1243	Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients: a phosphorous-31 magnetic resonance spectroscopy study. 2005 , 46, 1085-92	46
1242	Novel metabolic risk factors for heart failure. 2005 , 46, 2054-60	82
1241	Effect of bosentan (ETA/ETB receptor antagonist) on metabolic changes during stress and diabetes. 2005 , 51, 107-15	17
1240	Molecular Cardiology. 2005 ,	
1239	Diabetes and Cardiovascular Disease. 2005 ,	6
1238	Diabetic cardiomyopathy: the search for a unifying hypothesis. 2006 , 98, 596-605	465
1237	Left ventricular diastolic dysfunction in diabetic patients: pathophysiology and therapeutic implications. 2006 , 6, 219-30	26
1236	Thiazolidinediones in patients with diabetes mellitus and heart failure : implications of emerging data. 2006 , 6, 297-304	11
1235	Cardiomyopathy of insulin resistance. 2006 , 2, 13-23	4
1234	[Diabetic miocardiopathy]. 2006 , 127, 584-94	7

1233	Paradoxical increase in ventricular torsion and systolic torsion rate in type I diabetic patients under tight glycemc control. 2006 , 47, 384-90		95
1232	Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. 2006 , 47, 598-604		193
1231	Management of asymptomatic patients with reduced left ventricular ejection fraction. 2006 , 12, e26-8		4
1230	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). 2007 , 28, 88-136		889
1229	An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. 2006 , 151, 91		108
1228	Causes and characteristics of diabetic cardiomyopathy. 2006 , 3, 108-17		89
1227	Left ventricular dysfunction and remodeling in streptozotocin-induced diabetic rats. 2006 , 70, 327-34		49
1226	Angiotensin II receptor antagonist attenuates expression of aging markers in diabetic mouse heart. 2006 , 70, 482-8		23
1225	Cardioprotective mechanisms of the kallikrein-kinin system in diabetic cardiopathy. 2006 , 15, 22-9		24
1224	The effect of type 2 diabetes on diastolic function. 2006 , 38, 1384-8		21
1223	Myocardial performance in conscious streptozotocin diabetic rats. <i>Cardiovascular Diabetology</i> , 2006 , 5, 26	8.7	37
1222	Therapeutic effect of green tea extract on advanced glycation and cross-linking of collagen in the aorta of streptozotocin diabetic rats. 2006 , 33, 351-7		30
1221	Insulin status differentially affects energy transduction in cardiac mitochondria from male and female rats. 2006 , 8, 67-74		18
1220	Abnormal EKG stress test in rats with type 1 diabetes is deterred with low-intensity exercise programme. 2006 , 43, 66-74		12
1219	The use of B-type natriuretic peptide in the management of patients with diabetes and acute dyspnoea. 2006 , 49, 629-36		6
1218	Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. 2006 , 49, 2256-62		76
1217	Obesity and insulin resistance: effects on cardiac structure, function, and substrate metabolism. 2006 , 8, 451-6		29
1216	Predictors of improved left ventricular systolic function in an urban cardiomyopathy program. <i>American Journal of Cardiology</i> , 2006 , 98, 1622-6	3	3

1215	Prevençã de la diabetes mellitus en los pacientes con insuficiencia cardiaca. 2006 , 6, 50C-57C		
1214	The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. 2006 , 7, 40-4		37
1213	N(epsilon)-(carboxymethyl)lysine depositions in intramyocardial blood vessels in human and rat acute myocardial infarction: a predictor or reflection of infarction?. 2006 , 26, 2497-503		36
1212	Myocardial infarction and heart failure in the db/db diabetic mouse. 2006 , 290, H146-53		83
1211	Review: Heart failure complicating acute myocardial infarction in patients with diabetes: pathophysiology and management strategies. 2006 , 6, 191-196		
1210	Heart failure and nephropathy: catastrophic and interrelated complications of diabetes. 2006 , 1, 193-208		44
1209	WY 14,643 inhibits human aldose reductase activity. 2006 , 21, 569-73		9
1208	Asymptomatic cardiomyopathy in children and adolescents with type 1 diabetes mellitus: association of echocardiographic indicators with duration of diabetes mellitus and metabolic parameters. 2006 , 19, 713-26		11
1207	Abnormal left ventricular energy metabolism in obese men with preserved systolic and diastolic functions is associated with insulin resistance. <i>Diabetes Care</i> , 2007 , 30, 1520-6	14.6	51
1206	Hypersensitivity of myofilament response to Ca ²⁺ in association with maladaptation of estrogen-deficient heart under diabetes complication. 2007 , 292, R844-51		15
1205	Angiotensin II and the cardiac complications of diabetes mellitus. 2007 , 13, 2721-9		18
1204	Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure. 2007 , 64, 931-6		28
1203	Impact of diabetes on left ventricular diastolic function in patients with arterial hypertension. 2007 , 9, 469-76		23
1202	Risk Factors for Development of Heart Failure. 2007 , 3, 1-9		1
1201	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). 2007 , 9, C3-C74		25
1200	Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. 2007 , 56, 641-6		206
1199	Clinical profile of chronic heart failure in elderly women. 2002 , 11, 318-23		7
1198	Dysglycemia and heart failure hospitalization: what is the link?. 2007 , 115, 1334-5		8

1197	The evaluation of cardiac and peripheral arterial disease in patients with diabetes mellitus. 2007 , 32, 109-42	3
1196	Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. 2007 , 335, 497	242
1195	Endocrine Disorders and the Heart. 2007 , 2295-2330	1
1194	Myocardial lipid accumulation in the diabetic heart. 2007 , 116, 1110-2	18
1193	Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients--reversal by chronic angiotensin II type 1A receptor blockade. 2007 , 71, 524-9	45
1192	Atrial natriuretic peptide in diabetic and nondiabetic patients with and without heart transplantation. 2007 , 39, 1580-5	3
1191	Prevalence and prognosis of left ventricular systolic dysfunction in asymptomatic diabetic patients without known coronary artery disease referred for stress single-photon emission computed tomography and assessment of left ventricular function. 2007 , 154, 567-74	24
1190	Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 2007 , 154, 277.e1-8	106
1189	Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: A report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 2007 , 154, 647-654	43
1188	Impaired inotropic response in type 2 diabetes mellitus: a strain rate imaging study. 2007 , 20, 548-55	43
1187	Dietary supplementation with vitamin E ameliorates cardiac failure in type I diabetic cardiomyopathy by suppressing myocardial generation of 8-iso-prostaglandin F2alpha and oxidized glutathione. 2007 , 13, 884-92	31
1186	Cardiac remodeling rather than disturbed myocardial energy metabolism is associated with cardiac dysfunction in diabetic rats. 2007 , 114, 195-201	31
1185	Early diastolic impairment of diabetic heart: the significance of right ventricle. 2007 , 114, 218-23	78
1184	Sulfonylurea therapy is associated with increased NT-proBNP levels in the treatment of type 2 diabetes. 2007 , 115, 312-7	11
1183	Impaired glucose tolerance: a possible contributor to left ventricular hypertrophy and diastolic dysfunction. 2007 , 118, 76-80	14
1182	Raised leptin concentrations among South Asian patients with chronic heart failure. 2007 , 122, 34-40	10
1181	Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. 2007 , 60, 525.e1-525.e64	7
1180	Beneficios adicionales del tratamiento con candesartán en la insuficiencia cardíaca. Programa CHARM. 2007 , 24, 34-42	

1179	Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. 2007 , 115, 1371-5	146
1178	Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. 2007 , 23, 21-45	110
1177	Diabetic cardiomyopathy revisited. 2007 , 115, 3213-23	1161
1176	Heart failure in the diabetic patient. 2007 , 25, 523-38; vi	11
1175	Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. 2007 , 30, 741-53	57
1174	The epidemiology of congestive heart failure in hyperglycemia below the threshold for diabetes: A critical review. 2007 , 1, 273-278	
1173	Diabetes and heart failure: the role of thiazolidinediones in managing these partners in crime. 2007 , 50, 37-9	5
1172	[Diabetic cardiomyopathy]. 2007 , 51, 160-7	10
1171	GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES. 2007 , 3, 88-111	2
1170	[Diabetic nephropathy and cardiac disease]. 2007 , 51, 244-56	7
1169	Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. <i>American Journal of Cardiology</i> , 2007 , 99, 113B-132B	3 89
1168	Presence of biventricular dysfunction in patients with type II diabetes mellitus. 2007 , 13, 78-80	18
1167	Role of exercise and metabolism in heart failure with normal ejection fraction. 2007 , 49, 263-74	10
1166	Role of gender in heart failure with normal left ventricular ejection fraction. 2007 , 49, 241-51	99
1165	La diabetes mellitus tipo 2 como enfermedad cardiovascular. 2007 , 7, 9A-22A	1
1164	Diabetic cardiomyopathy and reactive oxygen species (ROS) related parameters in male and female rats: A comparative study. 2007 , 22, 84-90	18
1163	Myocardial metabolism and cardiac performance in obesity and insulin resistance. 2007 , 9, 143-9	26
1162	Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. 2007 , 50, 1977-1986	102

1161	Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. 2007 , 102, 500-7	151
1160	The impact of diabetes on heart failure: opportunities for intervention. 2007 , 4, 70-7	4
1159	Diabetic cardiomyopathy. 2007 , 9, 467-73	28
1158	What is the best myocardial perfusion protocol in diabetic patients?. 2008 , 24, 183-4	
1157	[Diabetes mellitus and heart failure: epidemiology and therapy]. 2008 , 33, 178-83	3
1156	Cardiomyopathy in type 2 diabetes: update on pathophysiological mechanisms. 2008 , 33, 184-90	37
1155	[Diabetes mellitus and heart failure - incidence and surgical therapy options]. 2008 , 33, 206-10	1
1154	Cardiovascular genetic medicine: genomic assessment of prognosis and diagnosis in patients with cardiomyopathy and heart failure. 2008 , 1, 225-31	10
1153	Associations of insulin resistance and type 2 diabetes to heart failure: Epidemiology, potential mechanisms, and clinical perspectives. 2008 , 2, 60-65	1
1152	Cardiovascular impairment in children, adolescents, and young adults with type 1 diabetes mellitus (T1DM). 2008 , 167, 877-84	20
1151	Diacylglycerol kinase zeta inhibits myocardial atrophy and restores cardiac dysfunction in streptozotocin-induced diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2008 , 7, 2	8.7 26
1150	Myocardial involvement during the early course of type 2 diabetes mellitus: usefulness of myocardial performance index. 2008 , 6, 27	10
1149	A novel function of bamboo extract in relieving lipotoxicity. 2008 , 22, 675-80	11
1148	Risk stratification in women enrolled in the Acute Decompensated Heart Failure National Registry Emergency Module (ADHERE-EM). 2008 , 15, 151-8	22
1147	Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy. 2008 , 31, 1425-32	28
1146	Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?. 2008 , 10, 312-28	21
1145	The PPARGC1A Gly482Ser polymorphism is associated with left ventricular diastolic dysfunction in men. 2008 , 8, 37	13
1144	Type 2 diabetes mellitus and heart failure. 2008 , 28, 170-92	23

1143	Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). <i>American Journal of Cardiology</i> , 2008 , 101, 634-8	3	103
1142	Inducible nitric oxide synthase depresses cardiac contractile function in Zucker diabetic fatty rats. 2008 , 579, 253-9		16
1141	The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. 2008 , 590, 276-80		48
1140	Is albuminuria an indicator of myocardial dysfunction in diabetic patients without overt heart disease? A study with Doppler strain and strain rate imaging. 2008 , 57, 448-52		19
1139	Are the available experimental models of type 2 diabetes appropriate for a gender perspective?. 2008 , 57, 6-18		65
1138	Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. 2008 , 51, 93-102		266
1137	Diabetic retinopathy and risk of heart failure. 2008 , 51, 1573-8		90
1136	Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. 2008 , 51, 1775-83		263
1135	Diastolic heart failure. 2008 , 37, 405-16		26
1134	Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. 2008 , 121, 748-57		356
1133	B-type natriuretic peptide, a marker of asymptomatic left ventricular dysfunction in type 2 diabetic patients. 2008 , 34, 355-62		29
1132	Left ventricular diastolic dysfunction in normotensive diabetic patients in various age strata. 2008 , 79, 91-6		16
1131	Thiazolidinediones in type 2 diabetes: a cardiology perspective. 2008 , 42, 1466-74		35
1130	Insulin resistance: a potential new target for therapy in patients with heart failure. 2008 , 26, 203-13		38
1129	Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. 2008 , 24, 21-40		78
1128	Diabetes-related metabolic perturbations in cardiac myocyte. 2008 , 34 Suppl 1, S3-9		34
1127	Heart failure with preserved ejection fraction: hypertension, diabetes, obesity/sleep apnea, and hypertrophic and infiltrative cardiomyopathy. 2008 , 4, 87-97		36
1126	Hypertension and the older diabetic. 2008 , 24, 489-501, vi-vii		8

1125	ATP production and TCA activity are stimulated by propionyl-L-carnitine in the diabetic rat heart. 2008 , 9, 83-91	12
1124	Early detection and significance of structural cardiovascular abnormalities in patients with Type 2 diabetes mellitus. 2008 , 6, 109-25	9
1123	Diabetic heart disease. 2006 , 92, 296-300	52
1122	Hypertension and diabetes. 2008 , 45, 82-106	42
1121	Diabetes Mellitus. 2008 , 333-342	
1120	Diabetes, left ventricular systolic dysfunction, and chronic heart failure. 2008 , 29, 1224-40	152
1119	Left ventricular diastolic function in normotensive type-2 diabetic subjects. 2008 , 100, 1066-72	5
1118	Preservation of heart function in diabetic rats by the combined effects of muscle cell implantation and insulin therapy. 2008 , 10, 14-21	4
1117	Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes. 2008 , 10, 380-7	23
1116	Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts. 2008 , 294, H2078-87	86
1115	Women younger than 65 years with diabetes mellitus are a high-risk group after myocardial infarction: a report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). 2008 , 94, 1565-70	41
1114	Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy. 2008 , 10, 298-307	42
1113	BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. 2008 , 10, 252-9	77
1112	Temporal changes in cardiac force- and flow-generation capacity, loading conditions, and mechanical efficiency in streptozotocin-induced diabetic rats. 2008 , 294, H867-74	4
1111	Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. 2008 , 168, 2138-45	371
1110	Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. 2008 , 117, 2544-65	394
1109	Cardiac muscle protein catabolism in diabetes mellitus: activation of the ubiquitin-proteasome system by insulin deficiency. 2008 , 149, 5384-90	31
1108	The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure. 2008 , 6, 292-300	60

1107	Prevention of incipient diabetic cardiomyopathy by high-dose thiamine. 2008 , 33, 459-72	28
1106	Silent myocardial infarction in women with type II diabetes mellitus and microalbuminuria. 2008 , 4, 705-12	5
1105	Cardiac and renal function are progressively impaired with aging in Zucker diabetic fatty type II diabetic rats. <i>Oxidative Medicine and Cellular Longevity</i> , 2009 , 2, 328-34	6.7 34
1104	Should we treat prehypertension in diabetes? What are the cons?. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S280-34.6	4
1103	Glucose management, heart failure and transplantation. 2009 , 5, 12-5	2
1102	Energy metabolism in the normal and in the diabetic heart. 2009 , 15, 836-40	26
1101	The 6th Annual World Congress on the Insulin Resistance Syndrome. <i>Diabetes Care</i> , 2009 , 32, e114-21	14.6 1
1100	Dimethylthiourea normalizes velocity-dependent, but not force-dependent, index of ventricular performance in diabetic rats: role of myosin heavy chain isozyme. 2009 , 297, H1411-20	3
1099	Decreased cardiac expression of vascular endothelial growth factor and redox imbalance in murine diabetic cardiomyopathy. 2009 , 297, H829-35	37
1098	Heart failure in patients hospitalized with acute coronary syndromes: observations from the Gulf Registry of Acute Coronary Events (Gulf RACE). 2009 , 11, 1135-42	25
1097	Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density. 2009 , 23, 2176-85	27
1096	Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. 2009 , 95, 1920-4	23
1095	The incidence of heart failure among nondiabetic patients with and without impaired fasting glucose. 2009 , 23, 224-8	7
1094	Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options. 2009 , 23, 273-82	27
1093	Effect of correction of hyperglycemia on left ventricular function in non-insulin-dependent (type 2) diabetics. 1983 , 213, 363-8	49
1092	Impaired left ventricular filling in young female diabetics. An echocardiographic study. 1984 , 216, 509-16	49
1091	Left ventricular function in newly diagnosed non-insulin-dependent (type 2) diabetics evaluated by systolic time intervals and echocardiography. 1985 , 217, 379-88	26
1090	REFERENCES. 2009 , 222, 58-69	

1089	Early heart failure in the population. The study of men born in 1913. 1988 , 223, 197-209		30
1088	Factors contributing to left ventricular diastolic dysfunction in long-term type I diabetic subjects. 1988 , 224, 249-56		20
1087	Prevalence and significance of cardiometabolic risk factors in children with type 1 diabetes. 2009 , 4, 50-6		27
1086	Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure. <i>American Journal of Cardiology</i> , 2009 , 103, 88-92	3	32
1085	Role of apoptosis in cardiovascular disease. 2009 , 14, 536-48		254
1084	Insulin resistance and heart failure. 2009 , 6, 89-94		24
1083	[ESC/EASD joint guidelines on diabetes and cardiovascular diseases]. 2009 , 34, 21-9		3
1082	Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model--the Zucker diabetic rat. <i>Cardiovascular Diabetology</i> , 2009 , 8, 16	8.7	39
1081	Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. <i>Cardiovascular Diabetology</i> , 2009 , 8, 58	8.7	88
1080	Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. 2009 , 10, 12		39
1079	Quantitative assessment of left ventricular and left atrial functions by strain rate imaging in diabetic patients with and without hypertension. 2009 , 26, 262-71		74
1078	Quantitative analysis of the magnitude and time delay of cyclic variation of myocardial backscatter from asymptomatic type 2 diabetes mellitus subjects. 2009 , 35, 1458-67		7
1077	Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study. 2009 , 15, 152-7		28
1076	Ghrelin inhibits apoptosis induced by high glucose and sodium palmitate in adult rat cardiomyocytes through the PI3K-Akt signaling pathway. 2009 , 155, 62-9		46
1075	Impaired insulin signaling accelerates cardiac mitochondrial dysfunction after myocardial infarction. 2009 , 46, 910-8		60
1074	Effects of diabetes mellitus in patients with heart failure and chronic kidney disease: a propensity-matched study of multimorbidity in chronic heart failure. 2009 , 134, 330-5		20
1073	Effects of diabetes mellitus, pressure-overload and their association on myocardial structure and function. 2009 , 22, 1190-8		11
1072	Abnormal glucose metabolism in acute myocardial infarction: influence on left ventricular function and prognosis. 2009 , 2, 592-9		26

1071	Diabetic cardiomyopathy--a distinct disease?. 2009 , 23, 347-60	53
1070	Effect of valsartan on left ventricular anatomy and systolic function and aortic elasticity. 2009 , 58, 682-8	2
1069	Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study. 2009 , 32, 229-37	15
1068	Diabetes mellitus and long-term outcome in heart failure patients after surgical ventricular restoration. 2009 , 88, 1451-6	3
1067	Can NT-proBNP predict risk of cardiovascular mortality within 10 years? Results from an epidemiological study of elderly patients with symptoms of heart failure. 2009 , 133, 233-40	8
1066	Heart failure. 2009 , 373, 941-55	131
1065	Translation of myocardial metabolic imaging concepts into the clinics. 2009 , 27, 291-310, Table of Contents	4
1064	Latin American guidelines on hypertension. Latin American Expert Group. 2009 , 27, 905-22	71
1063	Primary prevention of heart failure: what is the evidence?. 2009 , 24, 142-7	5
1062	Diabetic cardiomyopathy. 2009 , 116, 741-60	123
1061	Effect of diabetes and hypertension on left ventricular diastolic function in a high-risk population without evidence of heart disease. 2010 , 12, 454-61	61
1060	Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. 2010 , 28, 353-60	91
1059	A study of cardiovascular function in Tsumura Suzuki obese diabetes, a new model mouse of type 2 diabetes. 2010 , 33, 998-1003	6
1058	Neurohormonal profile of patients with heart failure and diabetes. 2010 , 18, 190-6	28
1057	Diabetic cardiomyopathy--to take a long story serious. 2010 , 35, 161-8	14
1056	[Diabetes and heart failure]. 2010 , 35, 140-6	3
1055	Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. 2010 , 53, 2546-53	100
1054	Transmitral E/A ratio decreases in association with abdominal fat accumulation in patients with impaired glucose tolerance or mild diabetes without left ventricular hypertrophy. 2010 , 25, 45-50	4

1053	Risk factors preceding type 2 diabetes and cardiomyopathy. 2010 , 3, 580-96		25
1052	Imaging Heart Failure in 2010. 2010 , 3, 303-316		
1051	Protective role of antioxidants in diabetes-induced cardiac dysfunction. 2010 , 10, 73-86		60
1050	The Framingham Study, diabetes mellitus and cardiovascular disease: turning back the clock. 2010 , 53, 45-51		36
1049	Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. 2010 , 20, 90-5		108
1048	Individual and joint associations of obesity and physical activity on the risk of heart failure. 2010 , 16, 292-9		8
1047	Diabetes is associated with impaired myocardial performance in patients without significant coronary artery disease. <i>Cardiovascular Diabetology</i> , 2010 , 9, 3	8.7	33
1046	Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2010 , 9, 63	8.7	61
1045	Pycnogenol improves left ventricular function in streptozotocin-induced diabetic cardiomyopathy in rats. 2010 , 24, 969-74		12
1044	Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. 2010 , 6, 883-903		127
1043	Is there a link between glucose levels and heart failure? An update. 2010 , 54, 488-97		8
1042	Cardiac output as a potential risk factor for abnormal brain aging. 2010 , 20, 813-21		72
1041	Guías Latinoamericanas de Hipertensión Arterial. 2010 , 29,		5
1040	Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes. 2010 , 6, 373-82		9
1039	Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes. 2010 , 163, 593-9		29
1038	Diabetes and heart failure in patients with coronary disease: separating markers from mediators. <i>Diabetes Care</i> , 2010 , 33, 2120-2	14.6	5
1037	Radionuclide imaging of myocardial metabolism. 2010 , 3, 211-22		56
1036	Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. 2010 , 299, H985-94		91

1035	Cardiovascular clinical trials in patients with diabetes mellitus: lessons from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study. 2010 , 121, 2453-5	4
1034	Physiologic basis and pathophysiologic implications of the diastolic properties of the cardiac muscle. 2010 , 2010, 807084	11
1033	Comorbidities in Heart Failure. 2010 , 257-270	1
1032	Effects of visfatin on proliferation and collagen synthesis in rat cardiac fibroblasts. 2010 , 42, 507-13	33
1031	The decreased expression of peroxisome proliferator-activated receptors delta (PPARdelta) is reversed by digoxin in the heart of diabetic rats. 2010 , 42, 637-42	13
1030	Neovascularization in diabetes. 2010 , 5, 99-111	5
1029	Sudden death risk in type 2 diabetic patients post-myocardial infarction: a "sweet" opportunity?. 2010 , 7, 1404-5	
1028	Cardiac Complications and Management. 355-376	
1027	Cardiotoxicity Associated with Thiazolidinediones. 2010 , 403-411	1
1026	Diabetic Cardiomyopathy: Mechanisms and Therapeutic Targets. 2010 , 7, e135-e143	103
1025	Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. 2010 , 55, 283-93	144
1024	Contribution of exercise echocardiography to the diagnosis of heart failure with preserved ejection fraction (HFpEF). 2010 , 96, 1024-8	51
1023	High-glucose condition reduces cardioprotective effects of insulin against mechanical stress-induced cell injury. 2010 , 87, 154-61	13
1022	Methylglyoxal-modified collagen promotes myofibroblast differentiation. 2010 , 29, 537-48	47
1021	Section 3: Prevention of Ventricular Remodeling, Cardiac Dysfunction, and Heart Failure. 2010 , 16, e38-e43	
1020	Section 5: Management of Asymptomatic Patients with Reduced Left Ventricular Ejection Fraction. 2010 , 16, e57-e60	0
1019	Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?. 2010 , 16, 761-8	31
1018	Diabetic cardiomyopathy. 2010 , 16, 971-9	91

1017	Palmitate attenuates myocardial contractility through augmentation of repolarizing Kv currents. 2010 , 48, 395-405	29
1016	Evidence for a role of immunoproteasomes in regulating cardiac muscle mass in diabetic mice. 2010 , 49, 5-15	38
1015	Glycemia and prognosis of patients with chronic heart failure--subanalysis of the Long-term Prospective Randomized Controlled Study Using Repetitive Education at Six-Month Intervals and Monitoring for Adherence in Heart Failure Outpatients (REMADHE) trial. 2010 , 159, 90-7	8
1014	Myocardial structure and function by echocardiography in relation to glucometabolic status in elderly subjects from 2 population-based cohorts: a cross-sectional study. 2010 , 159, 414-420.e4	32
1013	Myocardial Metabolism in Health and Disease. 2010 , 118-139	
1012	Long-term impact of diabetes in patients hospitalized with ischemic and non-ischemic heart failure. 2010 , 44, 37-44	16
1011	Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. 2011 , 11, 115-28	128
1010	Effect of diabetes on alteration of metabolism in cardiac myocytes: therapeutic implications. 2011 , 13, 1155-60	31
1009	Imaging Targets in Diabetic Cardiomyopathy: Current Status and Perspective. 2011 , 35, 353-362	3
1008	Type 2 diabetes and cardiovascular disease in South Asians. 2011 , 5, 45-56	156
1007	Hospitalization costs for heart failure in people with type 2 diabetes: cost-effectiveness of its prevention measured by a simulated preventive treatment. 2011 , 14, S20-3	7
1006	Brain Imaging in Behavioral Medicine and Clinical Neuroscience. 2011 ,	5
1005	Intensive glyceic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. 2011 , 162, 938-948.e2	116
1004	Metabolomics as a tool for cardiac research. 2011 , 8, 630-43	179
1003	Implications of prevalent and incident diabetes mellitus on left ventricular geometry and function in the ageing heart: the MONICA/KORA Augsburg cohort study. 2011 , 21, 189-96	12
1002	Cardiomyopathy in diabetics: a review of current opinion on the underlying pathological mechanisms. 2011 , 27, 175-181	1
1001	Heart Failure as a Consequence of Hypertension. 2011 , 435-444	
1000	Diabetic Cardiomyopathy. 2011 ,	

999	Heart Failure as a Consequence of Diabetic Cardiomyopathy. 2011 , 408-418		2
998	Heart Failure as a Consequence of Ischemic Heart Disease. 2011 , 355-371		
997	Absence of altered autophagy after myocardial ischemia in diabetic compared with nondiabetic mice. 2011 , 22, 479-83		9
996	Effects of nebivolol on vascular endothelial and myocardial function in diabetes mellitus. 2011 , 58, 56-64		6
995	Prevalence and prognostic implications of pre-diabetic state in patients with heart failure. 2011 , 75, 2833-9		39
994	Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy. 2011 , 75, 1717-27		43
993	Large artery biomechanics and diastolic dysfunction in patients with Type 2 diabetes. 2011 , 28, 54-60		17
992	Metformin improves cardiac function in rats via activation of AMP-activated protein kinase. 2011 , 38, 94-101		59
991	Characterization of the mechanisms of the increase in PPAR α expression induced by digoxin in the heart using the H9c2 cell line. 2011 , 163, 390-8		25
990	Valsartan protects against ER stress-induced myocardial apoptosis via CHOP/Puma signaling pathway in streptozotocin-induced diabetic rats. 2011 , 42, 496-502		54
989	Comparison of quantity of left ventricular scarring and remodeling by magnetic resonance imaging in patients with versus without diabetes mellitus and with coronary artery disease. <i>American Journal of Cardiology</i> , 2011 , 107, 1575-8	3	4
988	A propensity-matched study of the association of diabetes mellitus with incident heart failure and mortality among community-dwelling older adults. <i>American Journal of Cardiology</i> , 2011 , 108, 1747-53	3	10
987	[Cardial target-organ damage in diabetes]. 2011 , 52, 505-17		
986	Insulin resistance is not associated with myocardial steatosis in women. 2011 , 54, 1871-8		27
985	Peroxisome proliferator activated receptor-alpha (PPAR α) and PPAR gamma coactivator-1alpha (PGC-1 α) regulation of cardiac metabolism in diabetes. 2011 , 32, 323-8		29
984	Echocardiographic evaluation of cardiac function in asymptomatic type 2 diabetes mellitus. 2011 , 31, 76-81		
983	Potential of abnormalities in myocardial metabolism with the development of diabetes in women with obesity and insulin resistance. 2011 , 18, 421-9; quiz 432-3		33
982	What the radiologist needs to know about the diabetic patient. 2011 , 2, 193-203		4

981	Kein erhöhtes Mortalitätsrisiko durch Metformin-Therapie bei Diabetespacienten mit Herzinsuffizienz. 2011 , 7, 34-36		
980	Diabetes mellitus und Herzinsuffizienz. 2011 , 7, 247-253		
979	Change in comorbidity prevalence with advancing age among persons with heart failure. 2011 , 26, 1145-51		56
978	Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline. <i>Cardiovascular Diabetology</i> , 2011 , 10, 15	8.7	5
977	Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study. <i>Cardiovascular Diabetology</i> , 2011 , 10, 39	8.7	31
976	Molecular role of GATA binding protein 4 (GATA-4) in hyperglycemia-induced reduction of cardiac contractility. <i>Cardiovascular Diabetology</i> , 2011 , 10, 57	8.7	33
975	Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. <i>Cardiovascular Diabetology</i> , 2011 , 10, 80	8.7	41
974	Bayesian parameter estimation for characterizing the cyclic variation of echocardiographic backscatter to assess the hearts of asymptomatic type 2 diabetes mellitus subjects. 2011 , 37, 805-12		1
973	The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. 2011 , 7, 313-24		221
972	The role of PDI as a survival factor in cardiomyocyte ischemia. 2011 , 489, 47-65		31
971	Update on heart failure. 2011 , 11, 25-30		
970	Ryanodine receptor: a new therapeutic target to control diabetic cardiomyopathy. 2011 , 15, 1847-61		19
969	Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. 2011 , 18, 415-23		25
968	Cardiac resynchronization therapy reduces the risk of cardiac events in patients with diabetes enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT). 2011 , 4, 332-8		38
967	Lipotoxicity in type 2 diabetic cardiomyopathy. 2011 , 92, 10-8		133
966	Diabetes reduces left ventricular ejection fraction--irrespective of presence and extent of coronary artery disease. 2011 , 165, 945-51		18
965	One-hour postload plasma glucose levels and left ventricular mass in hypertensive patients. <i>Diabetes Care</i> , 2011 , 34, 1406-11	14.6	68
964	Macrophages modulate cardiac function in lipotoxic cardiomyopathy. 2012 , 303, H1366-73		32

963	Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. 2012 , 5, 493-503		104
962	NT-proBNP as a means of triage for the risk of hospitalisation in primary care. 2012 , 19, 55-61		7
961	Possible mechanism of the cardio-renal protective effects of AVE-0991, a non-peptide Mas-receptor agonist, in diabetic rats. 2012 , 13, 334-40		17
960	Effects of an aerobic and resistance training program on functional capacity and glucose regulation in patients with heart failure and diabetes. 2012 , 1, 43-48		
959	Gender effect on the relation between diabetes and hospitalization for heart failure. 2012 , 120, 51-5		7
958	Systolic myocardial dysfunction in patients with type 2 diabetes mellitus: identification at MR imaging with cine displacement encoding with stimulated echoes. 2012 , 265, 402-9		34
957	Intrauterine growth restriction coupled with hyperglycemia: effects on cardiac structure in adult rats. 2012 , 72, 344-51		13
956	[Diabetes and heart failure: a practically oriented critical appraisal]. 2012 , 137, 437-41		7
955	Prospective associations of B-type natriuretic peptide with markers of left ventricular function in individuals with and without type 2 diabetes: an 8-year follow-up of the Hoorn Study. <i>Diabetes Care</i> , 2012 , 35, 2510-4	14.6	23
954	Insulin resistance improves metabolic and contractile efficiency in stressed rat heart. 2012 , 26, 3118-26		32
953	Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. 2012 , 122, 1109-18		230
952	Serum uric acid and 1-h postload glucose in essential hypertension. <i>Diabetes Care</i> , 2012 , 35, 153-7	14.6	33
951	Do Clinical-Pathological Communication and Correlation Influence the Diagnosis and Incidence of Osteonecrosis?. 2012 , 138, A291.2-A291		
950	Type II diabetes mellitus is a risk factor for heart failure in pre-dialysis patients. 2012 , 16, 541-7		2
949	Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?. 2012 , 14, 1389-400		12
948	Molecular and cellular basis for diastolic dysfunction. 2012 , 9, 293-302		77
947	[Aerobic and strength training in patients with diabetes mellitus type 2 and heart failure]. 2012 , 37, 499-507		
946	Diabetes and the risk of heart failure. 2012 , 8, 125-33		43

945	Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. 2012 , 110, 1322-35	125
944	Cardiovascular disease and diabetes: the vulnerable patient. 2012 , 14, B4-B13	15
943	Reduction of heart failure by pharmacological inhibition or gene deletion of protein tyrosine phosphatase 1B. 2012 , 52, 1257-64	42
942	Left ventricular function and energy homeostasis in patients with type 1 diabetes with and without microvascular complications. 2012 , 154, 111-5	3
941	Association of left ventricular diastolic dysfunction with elevated NT-proBNP in type 2 diabetes mellitus patients with preserved ejection fraction: the supplementary role of tissue doppler imaging parameters and NT-proBNP levels. 2012 , 96, 179-86	9
940	Diabetic cardiomyopathy and diastolic heart failure -- difficulties with relaxation. 2012 , 97, 185-94	32
939	Lipid metabolism and toxicity in the heart. 2012 , 15, 805-12	327
938	Myocardial dysfunction in patients with type 2 diabetes mellitus: role of endothelial progenitor cells and oxidative stress. <i>Cardiovascular Diabetology</i> , 2012 , 11, 147	8.7 39
937	Exercise-induced cardiac performance in autoimmune (type 1) diabetes is associated with a decrease in myocardial diacylglycerol. 2012 , 113, 817-26	11
936	Sex and type 2 diabetes: obesity-independent effects on left ventricular substrate metabolism and relaxation in humans. 2012 , 20, 802-10	60
935	Diabetic cardiomyopathy: myth or reality?. 2012 , 105, 218-25	65
934	Low levels of circulating troponin as an intermediate phenotype in the pathway to heart failure. 2012 , 59, 490-2	7
933	Increase of myocardial performance by Rhodiola-ethanol extract in diabetic rats. 2012 , 144, 234-9	31
932	Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes. 2012 , 38, 298-308	11
931	Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension. 2012 , 7, e44470	50
930	Histological changes in the heart and the proximal aorta in experimental diabetic rats fed with Piper sarmentsoum. 2012 , 9,	2
929	Diabetic Cardiomyopathy: Cardiac Changes, Pathophysiological Mechanisms, Biologic Markers, and the Available Therapeutic Armamentarium. 2012 ,	
928	[Assessment of diastolic function in children and adolescents with type 1 diabetes mellitus - are there early signs of diabetic cardiomyopathy?]. 2012 , 56, 226-32	0

927	The role of inflammation in diabetic cardiomyopathy. 2012 , 59		10
926	Increase of ATP-sensitive potassium (K(ATP)) channels in the heart of type-1 diabetic rats. <i>Cardiovascular Diabetology</i> , 2012 , 11, 8	8.7	17
925	FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. 2012 , 14, 549-62		30
924	Use of a new high-sensitivity assay for cardiac troponin T to stratify the risk of cardiovascular disease in outpatients with type-2 diabetes. 2012 , 3, 29-36		5
923	[Comorbidity, hypoglycaemia and appropriate selection of antidiabetic pharmacotherapy in diabetic patients with heart failure in clinical practice in Germany. Results of the DiaRegis registry]. 2012 , 37, 294-300		8
922	The dilemma, causes and approaches to avoid recurrent hospital readmissions for patients with chronic heart failure. 2012 , 17, 345-53		18
921	Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. 2012 , 17, 325-44		240
920	A new insight of mechanisms, diagnosis and treatment of diabetic cardiomyopathy. 2012 , 41, 398-409		46
919	Diabetic cardiovascular disease: getting to the heart of the matter. 2012 , 5, 436-45		18
918	Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. 2012 , 107, 249		24
917	Effect of cardiovascular autonomic neuropathy (CAN) on left ventricular function in normotensive type 1 diabetic patients: A study by pulsed wave tissue Doppler echocardiography. 2012 , 64, 7-13		1
916	Immigrant status and increased risk of heart failure: the role of hypertension and life-style risk factors. 2012 , 12, 20		9
915	Diabetes. 2013 ,		7
914	Plaque vulnerability of coronary artery lesions is related to left ventricular dilatation as determined by optical coherence tomography and cardiac magnetic resonance imaging in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2013 , 12, 102	8.7	8
913	Exercise and diabetes have opposite effects on the assembly and O-GlcNAc modification of the mSin3A/HDAC1/2 complex in the heart. <i>Cardiovascular Diabetology</i> , 2013 , 12, 101	8.7	40
912	Diabetes, perioperative ischaemia and volatile anaesthetics: consequences of derangements in myocardial substrate metabolism. <i>Cardiovascular Diabetology</i> , 2013 , 12, 42	8.7	15
911	Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2013 , 12, 38	8.7	29
910	Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study. 2013 , 50, 597-606		28

909	Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?. 2013 , 30, 289-99		23
908	Insulin resistance and incident heart failure the ARIC study (Atherosclerosis Risk in Communities). 2013 , 1, 531-6		44
907	Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: a translational perspective for the cardiologist. 2013 , 169, 385-93		11
906	Adrenergic activation, fuel substrate availability, and insulin resistance in patients with congestive heart failure. 2013 , 1, 331-337		7
905	Increase in cardiac M2-muscarinic receptor expression is regulated by GATA binding protein 4 (GATA-4) in streptozotocin-induced diabetic rats. 2013 , 167, 436-41		4
904	Diabetic Cardiomyopathy in the Elderly. 2013 , 7, 490-494		1
903	Pioglitazone--do we really need it to manage type 2 diabetes?. 2013 , 7, 243-6		5
902	Recent advances in metabolic imaging. 2013 , 20, 1147-72		16
901	Post-stress left ventricular ejection fraction drop in patients with diabetes: a gated myocardial perfusion imaging study. 2013 , 13, 99		8
900	Treatment strategies for the prevention of heart failure. 2013 , 10, 331-40		7
899	High- and moderate-intensity training normalizes ventricular function and mechanoenergetics in mice with diet-induced obesity. 2013 , 62, 2287-94		61
898	Metformin in Diabetic Patients with Heart Failure: Safe and Effective?. 2013 , 7, 417-422		17
897	Mechanisms of diabetic complications. 2013 , 93, 137-88		1339
896	Insulin resistance and risk for incident heart failure. 2013 , 1, 537-9		7
895	Relation of heart-rate recovery to new onset heart failure and atrial fibrillation in patients with diabetes mellitus and preserved ejection fraction. <i>American Journal of Cardiology</i> , 2013 , 111, 748-53	3	23
894	Subclinical diastolic dysfunction in type 2 diabetic patients with and without carotid atherosclerosis: relationship with glyco-oxidation, lipid-oxidation and antioxidant status. 2013 , 163, 201-5		7
893	Worldwide risk factors for heart failure: a systematic review and pooled analysis. 2013 , 168, 1186-94		136
892	Severity of diabetic retinopathy is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. 2013 , 99, 287-91		14

891	Emerging role of epigenetics and miRNA in diabetic cardiomyopathy. 2013 , 22, 117-25	65
890	Myosin heads are displaced from actin filaments in the in situ beating rat heart in early diabetes. 2013 , 104, 1065-72	10
889	Effects of weight loss on myocardial energetics and diastolic function in obesity. 2013 , 29, 1043-50	53
888	Pioglitazone--do we really need it to manage type 2 diabetes?. 2013 , 7, 52-5	12
887	Cardiovascular disease and diabetes. 2012 , 771, 219-28	12
886	Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. 2013 , 18, 141-8	27
885	Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation. 2013 , 113, 1331-44	81
884	Increase of peroxisome proliferator-activated receptor α (PPAR α) by digoxin to improve lipid metabolism in the heart of diabetic rats. 2013 , 45, 364-71	12
883	Maternal diet-induced obesity and offspring cardiovascular health. 2013 , 4, 338-47	28
882	Activation of receptors α (PPAR α) by agonist (GW0742) may enhance lipid metabolism in heart both in vivo and in vitro. 2013 , 45, 880-6	12
881	Doxorubicin-Induced Cardiac Toxicity Is Mediated by Lowering of Peroxisome Proliferator-Activated Receptor α Expression in Rats. 2013 , 2013, 456042	15
880	An office-based approach to emotional and behavioral risk factor reduction for cardiovascular disease. 2013 , 21, 213-21	1
879	Associations between metabolomic compounds and incident heart failure among African Americans: the ARIC Study. 2013 , 178, 534-42	60
878	Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. 2013 , 6, 203-10	24
877	Taking diabetes to heart--deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. 2013 , 2, e000433	88
876	Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. 2013 , 6, 395-402	222
875	Influence of diabetes on left ventricular systolic and diastolic function and on long-term outcome after cardiac resynchronization therapy. <i>Diabetes Care</i> , 2013 , 36, 985-91	14.6 19
874	Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial. 2013 , 6, 164-70	14

873	Epidemiology of heart failure in Asia. 2013 , 77, 2209-17	153
872	Stereological study of the diabetic heart of male rats. 2013 , 29, 12-8	4
871	Left ventricular dysfunction in normotensive type II diabetic patients in Port Harcourt, Nigeria. 2013 , 9, 529-33	8
870	Association of serum uric acid with 2-hour postload glucose in Chinese with impaired fasting plasma glucose and/or HbA1c. 2013 , 8, e67759	4
869	Heart Failure in Women: Epidemiology, Prognosis, and Management. 2013 , 1055-1068	
868	Potential Target Molecules in Diabetic Cardiomyopathy: Hepatocyte Growth Factor (HGF) and Ryanodine Receptor 2 (RyR2). 2013 ,	
867	Significance of AT1 receptor independent activation of mineralocorticoid receptor in murine diabetic cardiomyopathy. 2014 , 9, e93145	7
866	Diabetes Mellitus and Heart Failure. 2014 , 9, 37-42	18
865	Diabetes, impaired fasting glucose, and heart failure: it's not all about the sugar. 2014 , 16, 1153-6	16
864	(-)-Epigallocatechin-3-gallate attenuated myocardial mitochondrial dysfunction and autophagy in diabetic Goto-Kakizaki rats. 2014 , 48, 898-906	32
863	Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation. 2014 , 2014, 847827	66
862	Impact of left ventricular assist device on diabetes management: an evaluation through case analysis and clinical impact. 2014 , 42, 116-22	2
861	Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. 2014 , 126, 471-82	59
860	Merit of ginseng in the treatment of heart failure in type 1-like diabetic rats. 2014 , 2014, 484161	16
859	Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. 2014 , 35, 657-64	225
858	Therapieoptionen des Diabetes mellitus Typ 2 bei hospitalisierten Patienten. 2014 , 9, R9-R20	
857	Hepatic protein tyrosine phosphatase 1B (PTP1B) deficiency protects against obesity-induced endothelial dysfunction. 2014 , 92, 607-17	14
856	Heart failure and dipeptidyl peptidase-4 inhibitors. 2014 , 16, 603-7	20

855	Improvement in glycemic control after left ventricular assist device implantation in advanced heart failure patients with diabetes mellitus. 2014 , 60, 675-80	8
854	Improvement in blood glucose control in patients with diabetes after implantation of left ventricular assist devices. 2014 , 60, 290-3	18
853	Heart failure as a risk factor for diabetes mellitus. 2014 , 129, 84-92	24
852	Rapid onset of cardiomyopathy in STZ-induced female diabetic mice involves the downregulation of pro-survival Pim-1. <i>Cardiovascular Diabetology</i> , 2014 , 13, 68	8.7 39
851	Advanced glycation end products: role in pathology of diabetic cardiomyopathy. 2014 , 19, 49-63	130
850	The influence of sex on cardiovascular outcomes associated with diabetes among older black and white adults. 2014 , 28, 316-22	9
849	Animal models of insulin resistance and heart failure. 2014 , 19, 1-13	32
848	Cardiovascular Risk in Diabetes Mellitus: Cause and Effect. 2014 , 2, 16-25	
847	Sex Differences and Diabetes Mellitus in Cardiovascular Function. 2014 , 159-176	
846	Co-morbidities in heart failure. 2014 , 19, 163-72	36
845	Identifying and interpreting novel targets that address more than one diabetic complication: a strategy for optimal end organ protection in diabetes. 2014 , 5, 1-20	3
844	Cardiogenic diabetes. 2014 , 19, 595-602	15
843	Imaging in diabetic cardiomyopathy. 2014 , 12, 475-486	
842	Sudden cardiac death and diabetes mellitus. 2014 , 28, 573-9	26
841	Conundrum of pathogenesis of diabetic cardiomyopathy: role of vascular endothelial dysfunction, reactive oxygen species, and mitochondria. 2014 , 386, 233-49	54
840	The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. 2014 , 383, 999-1008	642
839	Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. 2014 , 142, 375-415	354
838	Diabetic Cardiomyopathy. 2014 ,	2

837	Diabetes medications and heart failure: recognizing the risk. 2014 , 130, 1565-7	20
836	Ca(2+) mishandling and cardiac dysfunction in obesity and insulin resistance: role of oxidative stress. 2014 , 56, 408-15	26
835	Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus. 2014 , 16, 541	13
834	Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry. 2014 , 16, 409-18	33
833	Hyperglycemia inhibits cardiac stem cell-mediated cardiac repair and angiogenic capacity. 2014 , 130, S70-6	44
832	The association of leptin with dyslipidemia, arterial hypertension and obesity in Kyrgyz (Central Asian nation) population. 2014 , 7, 411	12
831	Role of cardiac MRI in diabetes. 2014 , 16, 449	12
830	Blood pressure and cardiovascular effects of new and emerging antidiabetic agents. 2014 , 16, 455	5
829	A comparison of risk factors for mortality from heart failure in Asian and non-Asian populations: an overview of individual participant data from 32 prospective cohorts from the Asia-Pacific Region. 2014 , 14, 61	21
828	Cardiovascular microRNAs: as modulators and diagnostic biomarkers of diabetic heart disease. <i>Cardiovascular Diabetology</i> , 2014 , 13, 44	8.7 74
827	Left ventricular systolic and diastolic function in normotensive type 2 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study. 2014 , 65, 877-82	7
826	Longitudinal myocardial strain alteration is associated with left ventricular remodeling in asymptomatic patients with type 2 diabetes mellitus. 2014 , 27, 479-88	74
825	Dietary patterns and 1-h post-load glucose in essential hypertension. 2014 , 24, 547-53	4
824	Cardiomyocyte health: adapting to metabolic changes through autophagy. 2014 , 25, 156-64	47
823	Cardiomyocyte specific peroxisome proliferator-activated receptor- β overexpression leads to irreversible damage in ischemic murine heart. 2014 , 102, 88-97	19
822	Low fasting plasma glucose level predicts morbidity and mortality in symptomatic adults with congenital heart disease. 2014 , 174, 306-12	20
821	Poor preoperative left ventricular function is associated with decreased insulin sensitivity during cardiac surgery. 2014 , 28, 631-4	1
820	Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. 2014 , 130, 554-64	182

819	New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering?. 2014 , 23, 997-1008		8
818	Fasting plasma glucose and incident heart failure risk: a population-based cohort study and new meta-analysis. 2014 , 20, 584-92		12
817	High glucose induces Rho/ROCK-dependent visfatin and type I procollagen expression in rat primary cardiac fibroblasts. 2014 , 10, 1992-8		10
816	Production of reactive oxygen species in the diabetic heart. Roles of mitochondria and NADPH oxidase. 2014 , 78, 300-6		101
815	Long Term Complications of Diabetes [A Review]. 2014 , 21, 347-355		
814	Partial inhibition of the ubiquitin-proteasome system ameliorates cardiac dysfunction following ischemia-reperfusion in the presence of high glucose. <i>Cardiovascular Diabetology</i> , 2015 , 14, 94	8.7	15
813	Earlier onset of diabetes-induced adverse cardiac remodeling in female compared to male mice. 2015 , 23, 1166-77		14
812	Prognostic Impact of Diabetes Mellitus in Chronic Heart Failure According to Presence of Ischemic Heart Disease [With Special Reference to Nephropathy]. 2015 , 79, 1764-72		6
811	Subendocardial Systolic Dysfunction in Asymptomatic Normotensive Diabetic Patients. 2015 , 79, 1749-55		41
810	Spatial modelling of type II diabetes outcomes: a systematic review of approaches used. 2015 , 2, 140460		13
809	Pharmacist intervention in the prevention of heart failure for high-risk elderly patients in the community. 2015 , 15, 178		10
808	A cohort study: temporal trends in prevalence of antecedents, comorbidities and mortality in Aboriginal and non-Aboriginal Australians with first heart failure hospitalization, 2000-2009. 2015 , 14, 66		8
807	Risk of Developing Coronary Artery Disease in Patients with Type 2 Diabetes Receiving Traditional Chinese Medicine Therapy. 2015 , 21, 604-9		5
806	Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. <i>Cardiovascular Diabetology</i> , 2015 , 14, 83	8.7	37
805	Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension. <i>Cardiovascular Diabetology</i> , 2015 , 14, 92	8.7	11
804	Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2015 , 14, 98	8.7	38
803	Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance. 2015 , 17, 95		21
802	Management of Noncardiac Comorbidities in Chronic Heart Failure. 2015 , 33, 300-15		22

801	Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. 2015 , 17, 725-34	17
800	Incidence and predictors of rehospitalization of acute heart failure patients. 2015 , 56, 219-25	25
799	Endoplasmic Reticulum Stress and Heart Complication in Diabetes. 2015 , 6,	2
798	A new Agkistrodon halys venom-purified protein C activator prevents myocardial fibrosis in diabetic rats. 2015 , 56, 439-46	5
797	Diabetic Cardiovascular Disease Induced by Oxidative Stress. 2015 , 16, 25234-63	240
796	The history of stress hyperglycaemia. 2015 , 45, 238-47	1
795	The Bioenergetics of Isolated Mitochondria from Different Animal Models for Diabetes. 2016 , 12, 66-80	5
794	Cardioprotective Activity of Pongamia pinnata in Streptozotocin-Nicotinamide Induced Diabetic Rats. 2015 , 2015, 403291	45
793	Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. 2015 , 385, 2107-17	188
792	Biomarkers of Cardiometabolic Risk, Inflammation and Disease. 2015 ,	2
791	Targeting caveolin-3 for the treatment of diabetic cardiomyopathy. 2015 , 151, 50-71	14
790	Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association. 2015 , 132, 2424-47	168
789	Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study. 2015 , 5, e007959	21
788	Diabetes and the female disadvantage. 2015 , 11, 833-9	24
787	Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls. 2015 , 7, 779-90	17
786	Programming of cardiovascular disease across the life-course. 2015 , 83, 122-30	44
785	Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor α . 2015 , 131, 795-804	86
784	Hydrogen sulfide attenuates high fat diet-induced cardiac dysfunction via the suppression of endoplasmic reticulum stress. 2015 , 46, 145-56	66

783	Presentation blood glucose and death, hospitalization, and future diabetes risk in patients with acute heart failure syndromes. 2015 , 36, 924-31	43
782	Prediction of heart failure in patients with type 2 diabetes mellitus- a systematic review and meta-analysis. 2015 , 108, 55-66	23
781	Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFkB-p65 and histone 3. 2015 , 26, 1298-307	161
780	PET Measurements of Organ Metabolism: The Devil Is in the Details. 2015 , 64, 2332-4	4
779	Mitofilin: Key factor in diabetic cardiomyopathy?. 2015 , 85, 292-3	7
778	Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes. 2015 , 101, 1139-48	28
777	Quantification of diabetes comorbidity risks across life using nation-wide big claims data. 2015 , 11, e1004125	35
776	Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. 2015 , 25, 697-705	9
775	Mitochondrial cardiomyopathy and related arrhythmias. 2015 , 7, 293-301	14
774	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. 2015 , 385, 2067-76	551
773	Newer targets and therapies for hypertension and dyslipidemia in diabetic patients. 2015 , 4, 11-16	
772	Myocardial metabolism in diabetic cardiomyopathy: potential therapeutic targets. 2015 , 22, 1606-30	35
771	Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. 2015 , 3, 356-66	193
770	Diabète et insuffisance cardiaque : la cardiomyopathie diabétique. 2015 , 9, 377-384	
769	Enzymatic and non-enzymatic post-translational modifications linking diabetes and heart disease. 2015 , 6, 16-7	2
768	Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study. 2015 , 8, 448-54	47
767	Heart Failure in Women—Insights from the Framingham Heart Study. 2015 , 29, 377-90	39
766	cAMP-dependent Protein Kinase (PKA) Signaling Is Impaired in the Diabetic Heart. 2015 , 290, 29250-8	28

765	NT-proBNP values in elderly heart failure patients with atrial fibrillation and diabetes. 2015 , 29, 1119-23	9
764	Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. 2015 , 3, 876-85	48
763	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. 2015 , 181, 239-44	82
762	Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes. 2015 , 21, 2-8	28
761	Alterations in connexin 43 during diabetic cardiomyopathy: competition of tyrosine nitration versus phosphorylation. 2015 , 7, 250-259	21
760	Concomitant diabetes mellitus and heart failure. 2015 , 40, 7-43	54
759	Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. 2015 , 1852, 232-42	192
758	Complications of Diabetes Mellitus. 2016 , 1484-1581	11
757	Heart Failure Hospitalization by Race/Ethnicity, Gender and Age in California: Implications for Prevention. 2016 , 26, 345-54	11
756	Present Insights on Cardiomyopathy in Diabetic Patients. 2016 , 12, 384-395	22
755	Type 2 Diabetes and Heart Failure: Challenges and Solutions. 2016 , 12, 249-55	42
754	Abnormal Glucose Tolerance Is Associated with a Reduced Myocardial Metabolic Flexibility in Patients with Dilated Cardiomyopathy. 2016 , 2016, 3906425	5
753	Diabetic Cardiomyopathy: Does the Type of Diabetes Matter?. 2016 , 17,	82
752	Diabetic Cardiomyopathy: A Forensic Perspective. 2016 , 6, 191-197	2
751	Inhibition of NADPH Oxidase 2 (NOX2) Prevents Oxidative Stress and Mitochondrial Abnormalities Caused by Saturated Fat in Cardiomyocytes. 2016 , 11, e0145750	54
750	Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. 2016 , 220, 595-601	50
749	Direct Evidence that Myocardial Insulin Resistance following Myocardial Ischemia Contributes to Post-Ischemic Heart Failure. 2015 , 5, 17927	22
748	Congestive Heart Failure. 2016 , 659-672	

747	Speckle Tracking Echocardiographic Imaging in Metabolic Cardiomyopathies. 2016 , 9, 1		
746	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study. 2016 , 164, 705-14		69
745	Insulin Signaling and Heart Failure. 2016 , 118, 1151-69		197
744	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. 2016 , 118, 1830-43		46
743	ZLN005 protects cardiomyocytes against high glucose-induced cytotoxicity by promoting SIRT1 expression and autophagy. 2016 , 345, 25-36		19
742	Diabetic cardiomyopathy: role of the E3 ubiquitin ligase. 2016 , 310, E473-83		12
741	Influence of diabetes on natriuretic peptide thresholds in screening for Stage B heart failure. 2016 , 21, 538-43		5
740	Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. 2016 , 118, 1313-26		478
739	Myocardial dysfunction and cardiovascular disease in type 2 diabetes. 2016 , 76, 271-81		12
738	The Type 2 Diabetic Heart: Its Role in Exercise Intolerance and the Challenge to Find Effective Exercise Interventions. 2016 , 46, 1605-1617		19
737	Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. 2016 , 16, 116		33
736	Glucolipotoxicity diminishes cardiomyocyte TFEB and inhibits lysosomal autophagy during obesity and diabetes. 2016 , 1861, 1893-1910		48
735	Problems, Pitfalls and Encouraging Information on Patients with Diabetes and Heart Failure. 2016 , 134, 411-2		
734	Epoxyeicosatrienoic Acid as Therapy for Diabetic and Ischemic Cardiomyopathy. 2016 , 37, 945-962		30
733	Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS. <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S210-8	14.6	17
732	Update on Echocardiographic Assessment in Diabetes Mellitus. 2016 , 18, 85		8
731	Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function. 2016 , 221, 114-21		24
730	AMPK in Cardiovascular Diseases. 2016 , 107, 179-201		24

729	AMP-activated Protein Kinase. 2016,	7
728	Effect of tighter glycemic control on cardiac function, exercise capacity, and muscle strength in heart failure patients with type 2 diabetes: a randomized study. 2016, 4, e000202	8
727	An observational study of the association among interatrial adiposity by computed tomography measure, insulin resistance, and left atrial electromechanical disturbances in heart failure. 2016, 95, e3912	16
726	Association of cardiac injury with iron-increased oxidative and nitrative modifications of the SERCA2a isoform of sarcoplasmic reticulum Ca(2+)-ATPase in diabetic rats. 2016, 127, 144-52	13
725	Myocardial Performance Index (Tei Index): A simple tool to identify cardiac dysfunction in patients with diabetes mellitus. 2016, 68, 83-7	12
724	Marital quality and loneliness as predictors for subjective health status in cardiac rehabilitation patients following percutaneous coronary intervention. 2016, 23, 1245-51	10
723	Efficacy of nobiletin, a citrus flavonoid, in the treatment of the cardiovascular dysfunction of diabetes in rats. 2016, 7, 3121-9	20
722	Forkhead box transcription factor 1: role in the pathogenesis of diabetic cardiomyopathy. <i>Cardiovascular Diabetology</i> , 2016, 15, 44	8.7 51
721	Tropisetron inhibits high glucose-induced calcineurin/NFAT hypertrophic pathway in H9c2 myocardial cells. 2016, 68, 485-93	19
720	Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1. 2016, 8, 63-75	26
719	Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. 2016, 9,	201
718	The Framingham Heart Study--67 years of discovery in metabolic disease. 2016, 12, 177-83	37
717	Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways. 2016, 310, H153-73	51
716	Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes. 2016, 21, 11-23	122
715	Identifying Key Intervention Opportunities During a Pregnancy Complicated by Diabetes: a Review of Acute Complications of Diabetes During Pregnancy. 2016, 16, 17	2
714	Comorbidities in Heart Failure: Are There Gender Differences?. 2016, 13, 1-12	25
713	Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities. 2016, 90, 84-93	242
712	8. Cardiovascular Disease and Risk Management. <i>Diabetes Care</i> , 2016, 39 Suppl 1, S60-71	14.6 196

711	The impact of an inverse correlation between plasma B-type natriuretic peptide levels and insulin resistance on the diabetic condition in patients with heart failure. 2016 , 65, 38-47	19
710	AHEAD score--Long-term risk classification in acute heart failure. 2016 , 202, 21-6	39
709	Type 2 Diabetes. 2016 ,	2
708	Early impairment in left ventricular longitudinal systolic function is associated with an increased risk of incident atrial fibrillation in patients with type 2 diabetes. 2017 , 31, 413-418	19
707	Diagnostic approaches for diabetic cardiomyopathy. <i>Cardiovascular Diabetology</i> , 2017 , 16, 28	8.7 111
706	Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes. 2017 , 119, 195-207	27
705	CTRP3 attenuates cardiac dysfunction, inflammation, oxidative stress and cell death in diabetic cardiomyopathy in rats. 2017 , 60, 1126-1137	100
704	Cross-Talk Between Insulin Signaling and G Protein-Coupled Receptors. 2017 , 70, 74-86	10
703	The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus. 2017 , 17, 38	31
702	Phosphoinositide 3-kinase (p110 β) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. 2017 , 131, 1345-1360	33
701	Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs. 2017 , 6, 1-7	18
700	Cats with diabetes mellitus have diastolic dysfunction in the absence of structural heart disease. 2017 , 225, 50-55	7
699	A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database. 2017 , 19, 635-642	20
698	MG53: Biological Function and Potential as a Therapeutic Target. 2017 , 92, 211-218	16
697	Are targeted therapies for diabetic cardiomyopathy on the horizon?. 2017 , 131, 897-915	48
696	Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities - A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort. 2017 , 14, 69-76	8
695	MicroRNAs in Diabetes and Its Vascular Complications. 2017 , 39-59	
694	Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). 2017 , 136, 248-258	519

693	Subclinical Myocardial Impairment in Metabolic Diseases. 2017 , 10, 692-703	26
692	Metformin and risk of long-term mortality following an admission for acute heart failure. 2017 , 18, 69-73	18
691	Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat. 2017 , 14, 423-433	25
690	Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy. 2017 , 58, R225-R240	30
689	Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention. 2017 , 1863, 2070-2077	46
688	Non-coding RNAs in the Vasculature. 2017 ,	
687	Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond. 2017 , 19, 23	58
686	Prevalence and Clinical Significance of Diabetes in Asian Versus White Patients With Heart Failure. 2017 , 5, 14-24	42
685	Diabetes Mellitus in Patients With Heart Failure: Bad for All, Worse for Some. 2017 , 5, 25-27	1
684	9. Cardiovascular Disease and Risk Management. <i>Diabetes Care</i> , 2017 , 40, S75-S87	14.6 174
683	Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus. 2017 , 14, 445-453	5
682	H3 Relaxin Protects Against Myocardial Injury in Experimental Diabetic Cardiomyopathy by Inhibiting Myocardial Apoptosis, Fibrosis and Inflammation. 2017 , 43, 1311-1324	35
681	Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. 2017 , 136, 1643-1658	256
680	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. 2017 , 33, 1342-1433	330
679	Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. 2017 , 248, 414-420	4
678	Impact of diabetes on heart failure incidence in adults with ischemic heart disease. 2017 , 31, 1597-1601	3
677	Glucose Homeostasis, Pancreatic Endocrine Function, and Outcomes in Advanced Heart Failure. 2017 , 6,	7
676	Coronary microvascular dysfunction in diabetes mellitus. 2017 , 45, 1901-1929	59

675	An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. 2017 , 113, 378-388		109
674	Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. 2017 , 6,		39
673	Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. <i>Cardiovascular Diabetology</i> , 2017 , 16, 63	8.7	35
672	In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. 2017 , 19, 54-65		92
671	Streptozotocin diabetes increases mRNA expression of ketogenic enzymes in the rat heart. 2017 , 1861, 307-312		24
670	PI3K inhibition Protects Against Diabetic Cardiomyopathy in Mice. 2017 , 70, 16-24		6
669	Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. 2017 , 19, 43-53		76
668	From Metabolic Exposome to Onset of Diabetic Cardiomyopathy. 2017 , 10, 115-117		7
667	La inhibici3n de la PI3K protege contra la miocardiopat3a diab3tica en ratones. 2017 , 70, 16-24		7
666	Association of Insulin Resistance and Glycemic Metabolic Abnormalities With LV Structure and Function in Middle Age: The CARDIA Study. 2017 , 10, 105-114		44
665	Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. 2017 , 43, 48-58		71
664	Atrial electromechanical delay, and left ventricular strain in pre-diabetic patients. 2017 , 14, 1-5		1
663	Higher hemoglobin A1c levels are associated with impaired left ventricular diastolic function and higher incidence of adverse cardiac events in patients with nonischemic dilated cardiomyopathy. 2017 , 32, 446-457		5
662	Sex Differences in Metabolic Cardiomyopathy. 2017 , 113, 370-377		26
661	Glycation abolishes the cardioprotective effects of albumin during ex vivo ischemia-reperfusion. 2017 , 5, e13107		2
660	[The safety of anti-diabetic drugs in heart failure]. 2017 , 158, 163-171		1
659	Metabolic and Biochemical Stressors in Diabetic Cardiomyopathy. 2017 , 4, 31		13
658	New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data. 2017 , 2017, 1253425		8

657	Natriuretic Peptide System Activation in Acute Heart Failure Patients with Diabetes. 2017 , 2017, 1426705		1
656	Effects of Momordica charantia (Bitter Melon) on Ischemic Diabetic Myocardium. 2017 , 22,		12
655	Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. <i>Cardiovascular Diabetology</i> , 2017 , 16, 93	8.7	21
654	Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure. <i>Cardiovascular Diabetology</i> , 2017 , 16, 102	8.7	16
653	Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease. 2017 , 16, 227		13
652	Sex and Gender Specific Aspects From Cells to Cardiovascular Disease. 2017 , 341-362		1
651	Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction. 2018 , 18, 181-193		47
650	The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. 2018 , 23, 303-323		27
649	The impact of oral anti-diabetic medications on heart failure: lessons learned from preclinical studies. 2018 , 23, 337-346		2
648	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. 2018 , 20, 853-872		264
647	Targeting Other Modifiable Risk Factors for the Prevention of Heart Failure: Diabetes, Smoking, Obesity, and Inactivity. 2018 , 12, 1		
646	Type I Diabetic Akita Mouse Model is Characterized by Abnormal Cardiac Deformation During Early Stages of Diabetic Cardiomyopathy with Speckle-Tracking Based Strain Imaging. 2018 , 45, 1541-1550		12
645	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. 2018 , 20, 888-895		65
644	Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management. 2018 , 34, 632-643		41
643	Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. 2018 , 137, 1060-1073		20
642	Molecular and clinical roles of incretin-based drugs in patients with heart failure. 2018 , 23, 363-376		1
641	Relation of Aortic Stiffness to Left Ventricular Remodeling in Younger Adults With Type 2 Diabetes. 2018 , 67, 1395-1400		21
640	Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. <i>Diabetes Care</i> , 2018 , 41, 1285-1291	14.6	23

639	Increased left ventricular mass index is present in patients with type 2 diabetes without ischemic heart disease. 2018 , 8, 926		16
638	Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance. 2018 , 23, 389-408		10
637	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME ² trial. 2018 , 39, 363-370		171
636	Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. 2018 , 122, 624-638		613
635	Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. 2018 , 71, 339-351		138
634	Clinical impact of oral antidiabetic medications in heart failure patients. 2018 , 23, 325-335		7
633	Effect of glucose-lowering therapies on heart failure. 2018 , 15, 282-291		34
632	The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. 2018 , 23, 445-459		4
631	Human embryonic stem cell-derived cardiomyocytes as an in vitro model to study cardiac insulin resistance. 2018 , 1864, 1960-1967		10
630	Increased risk of congestive heart failure in patients with acetaminophen poisoning: A nationwide cohort study. 2018 , 38, 766-772		1
629	Age affects the prognostic impact of diabetes in chronic heart failure. 2018 , 55, 271-278		5
628	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. 2018 , 16, 123-131		
627	Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2018 , 17, 54	8.7	17
626	Drug treatment of hypertension in older patients with diabetes mellitus. 2018 , 19, 633-642		2
625	Myocardial tissue characterization by contrast-enhanced cardiac magnetic resonance imaging in subjects with prediabetes, diabetes, and normal controls with preserved ejection fraction from the general population. 2018 , 19, 701-708		21
624	The role of NADPH oxidases in diabetic cardiomyopathy. 2018 , 1864, 1908-1913		39
623	Presence of micro- and macroalbuminuria and the association with cardiac mechanics in patients with type 2 diabetes. 2018 , 19, 1034-1041		16
622	Resistance exercise improves cardiac function and mitochondrial efficiency in diabetic rat hearts. 2018 , 470, 263-275		12

621	Cardiac apoptosis induced under high glucose condition involves activation of IGF2R signaling in H9c2 cardiomyoblasts and streptozotocin-induced diabetic rat hearts. <i>Biomedicine and Pharmacotherapy</i> , 2018 , 97, 880-885	7.5	13
620	Type 2 Diabetes and Heart Failure - More Scrutiny Wanted!. 2018 , 139, 37-39		1
619	9. Cardiovascular Disease and Risk Management:. <i>Diabetes Care</i> , 2018 , 41, S86-S104	14.6	370
618	Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. 2018 , 61, 21-28		268
617	Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. 2018 , 48, 52-108		46
616	Young FADOI and gender medicine: sex gender differences in cardiovascular disease. 2018 , 12, 23		1
615	Echocardiographic feature of diabetic cardiomyopathy: where are we now?. 2018 , 8, 47-56		18
614	Left ventricular assist device may improve glycemic control in diabetes mellitus patients but the reverse is not true. 2018 , 10, S4093-S4095		0
613	Low intake of digestible carbohydrates ameliorates the duodenal absorption of carbohydrates in mice with glucose metabolic disorders induced by sucralose. 2018 , 9, 6236-6244		1
612	Possibility of a New Therapeutic Strategy for Left Ventricular Dysfunction in Type 2 Diabetes. 2018 , 10, 799-805		10
611	OBSOLETE: Stage A Heart Failure: Identification and Management of Heart Failure Risk Factors. 2018 ,		
610	Leukocytic toll-like receptor 2 knockout protects against diabetes-induced cardiac dysfunction. 2018 , 506, 668-673		4
609	Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. <i>Frontiers in Physiology</i> , 2018 , 9, 1514	4.6	80
608	PI3Kinases in Diabetes Mellitus and Its Related Complications. 2018 , 19,		17
607	CCN5 knockout mice exhibit lipotoxic cardiomyopathy with mild obesity and diabetes. 2018 , 13, e0207228		6
606	Diabetes with heart failure increases methylglyoxal modifications in the sarcomere, which inhibit function. 2018 , 3,		33
605	Stage A Heart Failure: Identification and Management of Heart Failure Risk Factors. 2018 , 446-455		
604	[Adipose epicardial tissue association with subclinical systolic dysfunction detected by longitudinal strain in diabetic patients with poor glycemic control]. 2018 , 67, 310-314		2

603	Cardiac Glucolipototoxicity and Cardiovascular Outcomes. 2018 , 54,			5
602	Insulin reverses major portal hypertension-related derangements in rats with liver cirrhosis and diabetes. 2018 , 132, 2391-2405			3
601	Mechanisms of Drug-Induced Cardiovascular Toxicity: Cardiotoxicity Associated With Diabetes Medications. 2018 , 419-431			
600	Burden of Uncontrolled Metabolic Risk Factors and Left Ventricular Structure and Function in Patients With Type 2 Diabetes Mellitus. 2018 , 7, e008856			11
599	Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients. <i>Frontiers in Physiology</i> , 2018 , 9, 1575	4.6		76
598	Revisiting the Diabetes-Heart Failure Connection. 2018 , 18, 134			8
597	Routine use of HbA1c amongst inpatients hospitalised with decompensated heart failure and the association of dysglycaemia with outcomes. 2018 , 8, 13564			3
596	Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis. 2018 , 6, 823-830			28
595	Long noncoding RNAs: A new player in the prevention and treatment of diabetic cardiomyopathy?. 2018 , 34, e3056			14
594	Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. 2018 , 114, 1287-1303			57
593	Assessment of left ventricular systolic function by tissue Doppler imaging in controlled versus uncontrolled type 2 diabetic patients. 2018 , 70, 203-211			1
592	Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. 2018 , 20, 1281-1289			20
591	Histones and heart failure in diabetes. 2018 , 75, 3193-3213			14
590	Bioimpedance and New-Onset Heart Failure: A Longitudinal Study of >500'000 Individuals From the General Population. 2018 , 7,			16
589	Renal effects of sacubitril/valsartan in patients with diabetes. 2018 , 6, 519-521			4
588	Increased Protein Tyrosine Phosphatase 1B (PTP1B) Activity and Cardiac Insulin Resistance Precede Mitochondrial and Contractile Dysfunction in Pressure-Overloaded Hearts. 2018 , 7,			16
587	Left ventricular assist device implantation improves glycaemic control: a systematic review and meta-analysis. 2018 , 5, 1141-1149			5
586	Diabetic Cardiomyopathy: Impact of Biological Sex on Disease Development and Molecular Signatures. <i>Frontiers in Physiology</i> , 2018 , 9, 453	4.6		20

585	LncRNAs: Proverbial Genomic "Junk" or Key Epigenetic Regulators During Cardiac Fibrosis in Diabetes?. 2018 , 5, 28		13
584	Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness. 2018 , 72, 537-548		56
583	Inhibition of calcium/calmodulin-dependent kinase II restores contraction and relaxation in isolated cardiac muscle from type 2 diabetic rats. <i>Cardiovascular Diabetology</i> , 2018 , 17, 89	8.7	22
582	Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction. 2018 , 138, 198-205		169
581	Aged (Black) versus Raw Garlic against Ischemia/Reperfusion-Induced Cardiac Complications. 2018 , 19,		13
580	Reduction of Insulin Requirement After Starting Treatment With Sacubitril/Valsartan in a Patient with Diabetes Treated With Continuous Subcutaneous Insulin Infusion (CSII): A case report. 2018 , 12, 1254-1255		4
579	Diabetes and cardiovascular mortality: the impact of sex. 2018 , 6, 517-519		10
578	Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking. <i>Cardiovascular Diabetology</i> , 2018 , 17, 12	8.7	26
577	Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain. <i>Cardiovascular Diabetology</i> , 2018 , 17, 7	8.7	24
576	Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study. <i>Cardiovascular Diabetology</i> , 2018 , 17, 20	8.7	28
575	Exercise capacity in diabetes mellitus is predicted by activity status and cardiac size rather than cardiac function: a case control study. <i>Cardiovascular Diabetology</i> , 2018 , 17, 44	8.7	21
574	Exogenous Pancreatic Kallikrein Improves Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetes. 2018 , 9, 855		5
573	Double trouble: managing diabetic emergencies in patients with heart failure. 2018 , 35, 139-143		2
572	Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. 2018 , 6, 813-822		20
571	: Type 2 Diabetes and Readmission for Heart Failure. 2018 , 12, 1179546818779588		6
570	Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. 2019 , 40, 1-8		80
569	Risk of heart failure in a population with type 2 diabetes versus a population without diabetes with and without coronary heart disease. 2019 , 21, 112-119		15
568	Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. <i>Cardiovascular Diabetology</i> , 2019 , 18, 106	8.7	16

567	Atherosclerotic cardiovascular disease and heart failure: Determinants of risk and outcomes in patients with diabetes. 2019 , 62, 306-314	14
566	Heart Failure: Complications of Type 2 Diabetes. 2019 , 20, 1	
565	Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice. 2019 , 23, 6319-6330	21
564	Qishen Yiqi Drop Pill, a novel compound Chinese traditional medicine protects against high glucose-induced injury in cardiomyocytes. 2019 , 23, 6393-6402	7
563	Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte. 2019 , 20,	40
562	Clinical aspects of heart failure in individuals with diabetes. 2019 , 62, 1529-1538	9
561	GLUT4 expression and glucose transport in human induced pluripotent stem cell-derived cardiomyocytes. 2019 , 14, e0217885	10
560	Impact of Sex on Ventricular-Vascular Stiffness and Long-Term Outcomes in Heart Failure With Preserved Ejection Fraction: TOPCAT Trial Substudy. 2019 , 8, e012190	13
559	Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. 2019 , 20,	47
558	Clinical and Socioeconomic Predictors of Heart Failure Readmissions: A Review of Contemporary Literature. 2019 , 94, 1304-1320	11
557	Large Magnetoresistance in an Electric-Field-Controlled Antiferromagnetic Tunnel Junction. 2019 , 12,	8
556	Increased arrhythmia susceptibility in type 2 diabetic mice related to dysregulation of ventricular sympathetic innervation. 2019 , 317, H1328-H1341	8
555	Hypertension Treatment in Diabetes: Focus on Heart Failure Prevention. 2019 , 15, 551-563	3
554	Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. 2019 , 132, S3-S12	
553	Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. 2019 , 15, 519-530	0
552	The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart. 2019 , 33, 669-674	11
551	Enhanced cardiac expression of two isoforms of matrix metalloproteinase-2 in experimental diabetes mellitus. 2019 , 14, e0221798	9
550	Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study. 2019 , 19, 89	7

549	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. 2019 , 218, 57-65		3
548	Impact of Sex Differences and Diabetes on Coronary Atherosclerosis and Ischemic Heart Disease. 2019 , 8,		28
547	SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class. 2019 , 19, 64		7
546	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. 2019 , 140, e294-e324		168
545	Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. 2019 , 25, 584-619		30
544	Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. 2019 , 49, 389-395		11
543	Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study. <i>Cardiovascular Diabetology</i> , 2019 , 18, 79	8.7	16
542	Clinical Value of Circulating Microribonucleic Acids miR-1 and miR-21 in Evaluating the Diagnosis of Acute Heart Failure in Asymptomatic Type 2 Diabetic Patients. 2019 , 9,		17
541	The adaptive immune role of metallothioneins in the pathogenesis of diabetic cardiomyopathy: good or bad. 2019 , 317, H264-H275		4
540	70-year legacy of the Framingham Heart Study. 2019 , 16, 687-698		63
539	Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors. 2019 , 33, 567-571		4
538	Transgenic Expression of miR-133a in the Diabetic Akita Heart Prevents Cardiac Remodeling and Cardiomyopathy. 2019 , 6, 45		13
537	An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes. 2019 , 289, 119-124		2
536	Oral health as a gateway to overall health and well-being: Surveillance of the geriatric population in the United States. 2019 , 39, 354-361		11
535	Non-Invasive Imaging in Diabetic Cardiomyopathy. 2019 , 6,		2
534	Rationale, design and study protocol of the randomised controlled trial: Diabetes Interventional Assessment of Slimming or Training tO Lessen Inconspicuous Cardiovascular Dysfunction (the DIASTOLIC study). 2019 , 9, e023207		8
533	Diabetic Cardiomyopathy. 2019 , 124, 1160-1162		139
532	Epigenetics in the development of diabetic cardiomyopathy. 2019 , 11, 469-472		4

531	Congestive heart failure caused by silent ischemia and silent myocardial infarction : Diagnostic challenge in type 2 diabetes. 2019 , 44, 210-217		16
530	Glycemia Lowering Effect of an Aqueous Extract of Leaves in Diabetic Rodent Models. 2019 , 11,		3
529	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. 2019 , 139, 2528-2536		283
528	Evaluation of myocardial fibrosis in diabetes with cardiac magnetic resonance T1-mapping: Correlation with the high-level hemoglobin A1c. 2019 , 150, 72-80		13
527	Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients. 2019 , 20,		22
526	Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. 2019 , 12, 299-308		12
525	Trimetazidine prevents diabetic cardiomyopathy by inhibiting Nox2/TRPC3-induced oxidative stress. 2019 , 139, 311-318		16
524	Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials. <i>Cardiovascular Diabetology</i> , 2019 , 18, 47	8.7	13
523	Diabetic cardiomyopathy - A comprehensive updated review. 2019 , 62, 315-326		72
522	The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial. 2019 , 9, e026590		6
521	Diabetic cardiomyopathy: prevalence, determinants and potential treatments. 2019 , 10, 2042018819834869		39
520	Epidemiology of Atrial Fibrillation and Heart Failure: A Growing and Important Problem. 2019 , 37, 119-129		18
519	Diabetic cardiomyopathy: factual or factoid?. 2019 , 65, 61-69		5
518	The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes. 2019 , 35, 1283-1295		7
517	Applications of stem cells and bioprinting for potential treatment of diabetes. 2019 , 11, 13-32		16
516	Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. 2019 , 108, 868-877		9
515	10. Cardiovascular Disease and Risk Management:. <i>Diabetes Care</i> , 2019 , 42, S103-S123	14.6	335
514	Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism. 2019 , 20, 4612-4622		8

513	Influence of Complications of Diabetes Mellitus on Exercise Tolerance of Patients with Heart Failure: Focusing on autonomic nervous activity and heart rate response during cardiopulmonary exercise tests. 2019 , 22, 81-89		3
512	Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction. 2019 , 20,		8
511	Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship. <i>American Journal of Cardiology</i> , 2019 , 124 Suppl 1, S3-S11	3	14
510	Gender differences in cardiovascular disease. 2019 , 4, 100025		37
509	The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes. 2019 , 20,		7
508	Cardiomyopathie du diabétique, diabète et physiologie. 2019 , 11, S30-S45		
507	Characterising an Alternative Murine Model of Diabetic Cardiomyopathy. <i>Frontiers in Physiology</i> , 2019 , 10, 1395	4.6	15
506	HIIT Improves Left Ventricular Exercise Response in Adults with Type 2 Diabetes. 2019 , 51, 1099-1105		11
505	Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure: relation with ventricular stiffness and outcome. 2019 , 20, 81-90		8
504	Sex differences in heart failure. 2019 , 40, 3859-3868c		159
503	Heart Failure in Type 2 Diabetes Mellitus. 2019 , 124, 121-141		210
502	Of mice and men: models and mechanisms of diabetic cardiomyopathy. 2018 , 114, 2		87
501	Fibrotic Signaling in Cardiomyopathies. 2019 , 273-317		1
500	Sex-Specific Differences in Risk Factors for Development of Heart Failure in Women. 2019 , 15, 1-8		9
499	La cardiomyopathie diabétique : une vraie entité. 2019 , 2019, 7-12		
498	The imminent epidemic of atrial fibrillation and its concomitant diseases - Myocardial infarction and heart failure - A cause for concern. 2019 , 287, 162-173		14
497	Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart. 2019 , 11,		35
496	Efficient Mining Template of Predictive Temporal Clinical Event Patterns From Patient Electronic Medical Records. 2019 , 23, 2138-2147		4

495	GCN2 deficiency ameliorates cardiac dysfunction in diabetic mice by reducing lipotoxicity and oxidative stress. 2019 , 130, 128-139	18
494	Sex differences in the developmental origins of cardiometabolic disease following exposure to maternal obesity and gestational diabetes. 2019 , 44, 687-695	4
493	Microarray analysis of long non-coding RNA and mRNA expression profiles in diabetic cardiomyopathy using human induced pluripotent stem cell-derived cardiomyocytes. 2019 , 16, 57-68	8
492	A Review of Coronary Artery Bypass Grafting in the Indigenous Australian Population. 2019 , 28, 530-538	1
491	Mitochondrial NAD/NADH Redox State and Diabetic Cardiomyopathy. 2019 , 30, 375-398	50
490	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. 2020 , 75, 211-217	2
489	Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke. 2020 , 11, 110-124	3
488	Association Between Neighborhood Deprivation and Heart Failure Among Patients With Diabetes Mellitus: A 10-Year Follow-Up Study in Sweden. 2020 , 26, 193-199	5
487	Heart failure among people with Type 2 diabetes mellitus: real-world data of 289'954 people from a diabetes database. 2020 , 37, 1291-1298	2
486	[Gender differences in the mortality of people with type 2 diabetes: Asturias Study 2018]. 2020 , 34, 442-448	1
485	Methylglyoxal, a Highly Reactive Dicarbonyl Compound, in Diabetes, Its Vascular Complications, and Other Age-Related Diseases. 2020 , 100, 407-461	116
484	It's Not All About the Cardiomyocyte: Fibroblasts, Empagliflozin, and Cardiac Remodelling. 2020 , 36, 464-466	1
483	Differential prognostic impact of type 2 diabetes mellitus in women and men with heart failure with preserved ejection fraction. 2020 , 73, 463-470	8
482	Heart Failure as a Consequence of Ischemic Heart Disease. 2020 , 254-268.e6	2
481	Sex and Gender-Related Issues in Heart Failure. 2020 , 16, 121-130	8
480	Cardiac perfusion, structure, and function in type 2 diabetes mellitus with and without diabetic complications. 2020 , 21, 887-895	12
479	Inhibition of miR-21 alleviated cardiac perivascular fibrosis via repressing EndMT in T1DM. 2020 , 24, 910-920	25
478	Effects of Metformin on Left Ventricular Size and Function in Hypertensive Patients with Type 2 Diabetes Mellitus: Results of a Randomized, Controlled, Multicenter, Phase IV Trial. 2020 , 20, 283-293	3

477	Diabetes Mellitus Is an Independent Predictor for the Development of Heart Failure: A Population Study. 2020 , 95, 124-133		11
476	Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?. 2020 , 41, 1346-1353		21
475	Diabetic patients need higher furosemide doses: a report on acute and chronic heart failure patients. 2020 , 21, 21-26		4
474	Myocardial Function Assessed by Multi-Layered Two-Dimensional Speckle Tracking Analysis in Asymptomatic Young Subjects with Diabetes Mellitus Type 1. 2020 , 145, 80-87		1
473	Impact of diabetes on mortality and rehospitalization in acute heart failure patients stratified by ejection fraction. 2020 , 7, 297-305		4
472	CVOTs: What did the endocrinologist learn?. 2020 , 159, 107947		5
471	Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologist's Perspective: Lessons Learned from Cardiovascular Outcome Trials. 2019 , 17,		3
470	Si-Miao-Yong-An decoction preserves cardiac function and regulates GLC/AMPK/NF- κ B and GLC/PPAR γ /PGC-1 β pathways in diabetic mice. <i>Biomedicine and Pharmacotherapy</i> , 2020 , 132, 110817	7-5	3
469	Enhanced Catecholamine Flux and Impaired Carbonyl Metabolism Disrupt Cardiac Mitochondrial Oxidative Phosphorylation in Diabetes Patients. 2021 , 35, 235-251		4
468	Do Women with Diabetes Need More Intensive Action for Cardiovascular Reduction than Men with Diabetes?. 2020 , 20, 61		5
467	Inflammation, non-endothelial dependent coronary microvascular function and diastolic function-Are they linked?. 2020 , 15, e0236035		8
466	Pattern recognition receptor-mediated inflammation in diabetic vascular complications. 2020 , 40, 2466-2484		18
465	Myocardial glucotoxicity: Mechanisms and potential therapeutic targets. 2020 , 113, 736-748		6
464	The Potential Roles of Artemisinin and Its Derivatives in the Treatment of Type 2 Diabetes Mellitus. 2020 , 11, 585487		9
463	Reduced reticulum-mitochondria Ca transfer is an early and reversible trigger of mitochondrial dysfunctions in diabetic cardiomyopathy. 2020 , 115, 74		25
462	The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism. <i>Frontiers in Endocrinology</i> , 2020 , 11, 599355	5-7	5
461	Reduced fatty acid uptake aggravates cardiac contractile dysfunction in streptozotocin-induced diabetic cardiomyopathy. 2020 , 10, 20809		4
460	Blood Pressure, Congestion and Heart Failure with Preserved Ejection Fraction Among Patients with and Without Type 2 Diabetes Mellitus. A Cluster Analysis Approach from the Observational Registry DICUMAP. 2020 , 27, 399-408		0

459	Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC). 2020 , 9,		7
458	Role of AMP-activated protein kinase on cardio-metabolic abnormalities in the development of diabetic cardiomyopathy: A molecular landscape. 2020 , 888, 173376		11
457	Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2020 , 19, 184	8.7	6
456	10. Cardiovascular Disease and Risk Management:. <i>Diabetes Care</i> , 2020 , 43, S111-S134	14.6	296
455	Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. 2020 , 45 Suppl 1, 61-72		4
454	Early changes in myocyte contractility and cardiac function in streptozotocin-induced type 1 diabetes in rats. 2020 , 15, e0237305		6
453	Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus. 2021 , 45, 553-556		1
452	Cardioprotective effects of short-term empagliflozin treatment in db/db mice. 2020 , 10, 19686		6
451	Cellular Protein Quality Control in Diabetic Cardiomyopathy: From Bench to Bedside. 2020 , 7, 585309		5
450	SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy. 2020 , 14, 4775-4788		10
449	Blood Pressure Variability and Risk of Heart Failure in ACCORD and the VADT. <i>Diabetes Care</i> , 2020 , 43, 1471-1478	14.6	14
448	Upregulation of microRNA-532 enhances cardiomyocyte apoptosis in the diabetic heart. 2020 , 25, 388-399		6
447	Loss of function of transcription factor EB remodels lipid metabolism and cell death pathways in the cardiomyocyte. 2020 , 1866, 165832		11
446	Basic Mechanisms of Diabetic Heart Disease. 2020 , 126, 1501-1525		89
445	New pharmacotherapy for heart failure with reduced ejection fraction. 2020 , 18, 405-414		4
444	Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetes. 2020 , 9, 17-23		10
443	Irisin Improves Myocardial Performance and Attenuates Insulin Resistance in Spontaneous Mutation () Mice. 2020 , 11, 769		4
442	Coexisting Morbidities in Heart Failure: No Robust Interaction with the Left Ventricular Ejection Fraction. 2020 , 17, 133-144		1

441	Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes?. 2020 , 11, 2042018820928824		15
440	Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients. 2020 , 75, 1249-1262		25
439	Mitochondrial ROS Formation in the Pathogenesis of Diabetic Cardiomyopathy. 2020 , 7, 12		74
438	Resveratrol and Diabetic Cardiomyopathy: Focusing on the Protective Signaling Mechanisms. <i>Oxidative Medicine and Cellular Longevity</i> , 2020 , 2020, 7051845	6.7	8
437	Icariin Ameliorates Diabetic Cardiomyopathy Through Apelin/Sirt3 Signalling to Improve Mitochondrial Dysfunction. 2020 , 11, 256		17
436	Rationale and design of the EMPYREAN study. 2020 , 7, 3134-3141		4
435	Endothelial Dysfunction: A Contributor to Adverse Cardiovascular Remodeling and Heart Failure Development in Type 2 Diabetes beyond Accelerated Atherogenesis. 2020 , 9,		9
434	A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. 2020 , 41, 3421-3432		55
433	The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments. 2020 , 105,		3
432	The Peroxisome Proliferator-Activated Receptor-Gamma Coactivator-1 β -Heme Oxygenase 1 Axis, a Powerful Antioxidative Pathway with Potential to Attenuate Diabetic Cardiomyopathy. 2020 , 32, 1273-1290		6
431	Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials. 2020 , 14, 181-187		16
430	Myocardial Changes in Diabetic and Nondiabetic Nonhuman Primates. 2020 , 57, 332-343		2
429	NADPH Oxidase 2 Mediates Myocardial Oxygen Wasting in Obesity. 2020 , 9,		1
428	High-mobility group AT-hook 1 promotes cardiac dysfunction in diabetic cardiomyopathy via autophagy inhibition. 2020 , 11, 160		13
427	Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018. <i>Diabetes Care</i> , 2020 , 43, 921-924	14.6	30
426	Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. 2020 , 17, 585-607		139
425	De la insuficiencia cardiaca a la diabetes. ¿Existe un mecanismo común?. 2020 , 27, 7-11		
424	Association of Prediabetes With CKD Progression and Adverse Cardiovascular Outcomes: An Analysis of the CRIC Study. 2020 , 105,		8

423	Epicardial adipose tissue is tightly associated with exercise intolerance in patients with type 2 diabetes mellitus with asymptomatic left ventricular structural and functional abnormalities. 2020 , 34, 107552	6
422	Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential. 2020 , 34, 419-436	7
421	Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease. 2020 , 22, 813-820	2
420	Diabetic Cardiomyopathy and Ischemic Heart Disease: Prevention and Therapy by Exercise and Conditioning. 2020 , 21,	20
419	Diabetic cardiomyopathy: How can cardiac magnetic resonance help?. 2020 , 57, 1027-1034	9
418	Cycloviobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses. 2020 , 10, 6427	10
417	Incidence of heart failure among diabetic patients with ischemic heart disease: a cohort study. 2020 , 20, 181	1
416	NOD Mice Recapitulate the Cardiac Disturbances Observed in Type 1 Diabetes. 2021 , 14, 271-282	2
415	Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future. 2021 , 26, 953-960	1
414	Cardiovascular Disease in Women: From Pathophysiology to Novel and Emerging Risk Factors. 2021 , 30, 9-17	15
413	DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism. 2021 , 36, 136-146	6
412	Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology. 2021 , 47, 101185	13
411	Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study. 2021 , 16, 895-903	3
410	Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors. 2021 , 26, 377-390	4
409	Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications. 2021 , 12, 87-105	5
408	Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. 2021 , 18, 291-304	33
407	Diabetic Cardiomyopathy Progression is Triggered by miR122-5p and Involves Extracellular Matrix: A 5-Year Prospective Study. 2021 , 14, 1130-1142	10
406	Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology. 2021 , 114, 150-172	1

405	10. Cardiovascular Disease and Risk Management:. <i>Diabetes Care</i> , 2021 , 44, S125-S150	14.6	153
404	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. 2021 , 12, 1-51		5
403	Morphological characteristics in diabetic cardiomyopathy associated with autophagy. 2021 , 77, 30-40		4
402	Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure. 2021 , 39, 105-116		
401	Enkeloedeem. 2021 , 687-701		
400	Cardiovascular disease: Sex and gender evidence in acute ischemic syndrome and heart failure. 2021 , 101-127		
399	Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity. 2021 , 171-205		
398	Diabetes in the Arab World. 2021 , 1-24		
397	Sex and ethnic differences in the cardiovascular complications of type 2 diabetes. 2021 , 12, 20420188211034297		
396	Serum Individual Nonesterified Fatty Acids and Risk of Heart Failure in Older Adults. 2021 , 146, 351-358		3
395	Generating Ins2/miR-133aTg Mice to Model miRNA-Driven Cardioprotection of Human Diabetic Heart. 2021 , 2224, 113-121		2
394	Impact of peroxisome proliferator-activated receptor- α on diabetic cardiomyopathy. <i>Cardiovascular Diabetology</i> , 2021 , 20, 2	8.7	17
393	Diabetes in the Arab World. 2021 , 1029-1051		
392	Total flavonoids extracted from the leaves of <i>Murraya paniculata</i> (L.) Jack alleviate oxidative stress, inflammation and apoptosis in a rat model of diabetic cardiomyopathy. 2021 , 76, 104319		3
391	Diabetes-induced changes in cardiac voltage-gated ion channels. 2021 , 12, 1-18		7
390	Diabetes mellitus and atrial fibrillation—Untying the Gordian Knot. 2021 , 95-121		1
389	Heart Failure With Preserved Ejection Fraction. 2021 , 201-222		
388	MiR-34a inhibitor protects mesenchymal stem cells from hyperglycaemic injury through the activation of the SIRT1/FoxO3a autophagy pathway. 2021 , 12, 115		4

387	Fasting plasma glucose and subsequent cardiovascular disease among young adults: Analysis of a nationwide epidemiological database. 2021 , 319, 35-41	11
386	SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism. 2021 , 1	3
385	Evidence for human diabetic cardiomyopathy. 2021 , 58, 983-988	5
384	Diabetic Complications: An Update on Pathobiology and Therapeutic Strategies. 2021 ,	1
383	New approach for cardiac insulin resistance assessment using nuclear imaging: Moving research closer to practice. 2021 , 1	
382	Myocardial Ischemia-Reperfusion and Diabetes: Lessons Learned From Bedside to Bench. 2021 , 8, 660698	1
381	Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice. 2021 , 8, 1933-1943	7
380	Comparison of clinical outcomes and left ventricular remodeling after ST-elevation myocardial infarction between patients with and without diabetes mellitus. 2021 , 36, 1445-1456	2
379	A Novel ALDH2 Activator AD-9308 Improves Diastolic and Systolic Myocardial Functions in Streptozotocin-Induced Diabetic Mice. 2021 , 10,	1
378	The human aortic endothelium undergoes dose-dependent DNA methylation in response to transient hyperglycemia. 2021 , 400, 112485	9
377	Vildagliptin Attenuates Myocardial Dysfunction and Restores Autophagy via miR-21/SPRY1/ERK in Diabetic Mice Heart. 2021 , 12, 634365	5
376	Sex Differences in Heart Failure With Preserved Ejection Fraction. 2021 , 10, e018574	16
375	Concurrent diabetes and heart failure: interplay and novel therapeutic approaches. 2021 ,	4
374	Women With Diabetes Are at Increased Relative Risk of Heart Failure Compared to Men: Insights From UK Biobank. 2021 , 8, 658726	2
373	Novel Lesional Transcriptional Signature Separates Atherosclerosis With and Without Diabetes in Yorkshire Swine and Humans. 2021 , 41, 1487-1503	1
372	Association of Mean and Variability of HbA1c with Heart Failure in Patients with Type 2 Diabetes. 2021 , 10,	1
371	Heart failure at the crossroads of cardiology and diabetology. 2021 , 175, 108844	
370	Cardiovascular outcome trials in Type 2 diabetes: food for thought. 2021 , 17, 407-410	1

369	Role of microvascular dysfunction in left ventricular dysfunction in type 2 diabetes mellitus. 2021 , 35, 107907		0
368	Islet microangiopathy and augmented β cell loss in Japanese non-obese type 2 diabetes patients who died of acute myocardial infarction. 2021 , 12, 2149		1
367	Sex Differences of the Diabetic Heart. <i>Frontiers in Physiology</i> , 2021 , 12, 661297	4.6	3
366	Salidroside protects cardiac function in mice with diabetic cardiomyopathy via activation of mitochondrial biogenesis and SIRT3. 2021 , 35, 4579-4591		3
365	Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease. 2021 , 5, bvab083		1
364	Role of novel biomarkers in diabetic cardiomyopathy. 2021 , 12, 685-705		4
363	The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms. 2021 , 8, 695792		16
362	Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. 2021 , 169, 317-342		16
361	Osteocrin, a novel myokine, prevents diabetic cardiomyopathy via restoring proteasomal activity. 2021 , 12, 624		16
360	Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy - current and future perspectives. 2021 , 135, 1369-1387		2
359	Prevalence of Atherosclerotic Cardiovascular Disease, Heart Failure, and Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Primary Care Research Network-based Study. 2021 ,		2
358	Association between cardiac high-energy phosphate metabolism and whole body metabolism in healthy female adults. 2021 , 70, 393-399		0
357	Framingham Heart Study: JACC Focus Seminar, 1/8. 2021 , 77, 2680-2692		9
356	The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities. 2021 , 22,		6
355	Cardiovascular Magnetic Resonance as Pathophysiologic Tool in Diabetes Mellitus. <i>Frontiers in Endocrinology</i> , 2021 , 12, 672302	5.7	1
354	Trends and complications associated with acute new-onset heart failure: a National Readmissions Database-based cohort study. 2021 , 1		0
353	The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure. 2021 , 27, 1447-1455		2
352	Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares. 2021 , 26, 4534		0

351	Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus. 2021 , 45, 505-514		4
350	Electrical Features of the Diabetic Myocardium. Arrhythmic and Cardiovascular Safety Considerations in Diabetes. 2021 , 12, 687256		6
349	Sodium-glucose cotransporter-2 Inhibitors in Heart Failure: An Updated Systematic Review and Meta-analysis of 13 Randomized Clinical Trials Including 14,618 Patients With Heart Failure. 2021 , 78, 501-514		1
348	[Relaci3n entre enfermedad cardiovascular y renal en una muestra de pacientes con diabetes del mundo real]. 2021 ,		
347	The prognostic value of the triglyceride glucose index in patients with chronic heart failure and type 2 diabetes: A retrospective cohort study. 2021 , 177, 108786		8
346	Which drug is best for a patient with type 2 diabetes and heart failure?. 2021 , 34, 49-52		
345	Diabetes and heart failure notions from epidemiology including patterns in low-, middle- and high-income countries. 2021 , 177, 108822		0
344	Sex-specific temporal evolution of circulating biomarkers in patients with chronic heart failure with reduced ejection fraction. 2021 , 334, 126-134		0
343	Perioperative challenges in management of diabetic patients undergoing non-cardiac surgery. 2021 , 12, 1255-1266		0
342	Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy.. 2022 , 12, 1-17		2
341	Diabetes Mellitus and Heart Failure. 2021 , 10,		7
340	Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart Failure: COAPT Trial. 2021 , 9, 559-567		0
339	Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy. <i>Cardiovascular Diabetology</i> , 2021 , 20, 161	8.7	1
338	Diabetes in Patients With Heart Failure With Reduced Ejection Fraction During Hospitalization: A Retrospective Observational Study. <i>Frontiers in Endocrinology</i> , 2021 , 12, 727188	5.7	2
337	Dapagliflozin 3structure, synthesis, and new indications. 2021 , 68, 591-596		
336	Novel approaches to pharmacological management of type 2 diabetes in Japan. 2021 , 22, 2235-2249		0
335	Three-Dimensional Global Left Ventricular Myocardial Strain Reduced in All Directions in Subclinical Diabetic Cardiomyopathy: A Systematic Review and Meta-Analysis. 2021 , 10, e020811		1
334	Why the diabetic heart is energy inefficient: a ketogenesis and ketolysis perspective. 2021 , 321, H751-H755		2

333	Chronic Pharmacological Modulation of Mitochondrial Dynamics Alleviates Prediabetes-Induced Myocardial Ischemia-Reperfusion Injury by Preventing Mitochondrial Dysfunction and Programmed Apoptosis. 2021 , 1	1
332	A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus. 2021 , 134, 1076-1084	0
331	Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities. 2021 , 176, 113904	5
330	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. 2021 , 21, 41	0
329	Functional resilience of C57BL/6J mouse heart to dietary fat overload. 2021 , 321, H850-H864	0
328	Diabetes status-related differences in risk factors and mediators of heart failure in the general population: results from the MORGAM/BiomarCaRE consortium. <i>Cardiovascular Diabetology</i> , 2021 , 20, 195	8.7 0
327	Diabetic Cardiomyopathy: Clinical and Metabolic Approach. 2021 , 19, 487-498	1
326	Cardiac Phosphodiesterases Are Differentially Increased in Diabetic Cardiomyopathy. 2021 , 283, 119857	2
325	Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy. 2021 , 228, 107920	4
324	Detection of subclinical heart failure. 2022 , 20-50	0
323	A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure. 2021 , 12, 60-66	6
322	PET Measurement of Myocardial Metabolism. 2007 , 227-249	2
321	Regulation of Cardiac Function in Diabetes. 2003 , 353-371	1
320	Autonomic Neuropathy and Heart Disease. 1998 , 209-226	1
319	Hormonal Effects On Cardiac Performance. 1989 , 643-653	1
318	Clinical Manifestations of Diabetic Cardiomyopathy. 1996 , 1-22	1
317	The Cardiomyopathies. 1994 , 196-222	3
316	Metabolic Alterations in Diabetic Cardiomyopathy. 2014 , 3-25	1

315	Diastolic Dysfunction, Redox Stress, Extracellular Matrix Remodeling and Congestive Heart Failure in Diabetes Mellitus. 2003 , 563-582	1
314	Effect of diabetes mellitus on hemodynamic and cardiometabolic correlates in experimental myocardial infarction. 2001 , 498, 229-40	2
313	Etiology of Left Ventricular Dysfunction in End-Stage Renal Failure. 1992 , 105-115	1
312	PPAR/PGC-1 Regulation of Metabolism in Cardiac Disease. 2012 , 83-111	1
311	Pathophysiology and Clinical Recognition of Heart Failure. 2007 , 1379-1396	1
310	Altered Responsiveness of Vascular Smooth Muscle to Drugs in Diabetes. 1994 , 693-712	2
309	Oedeem, voeten. 2016 , 801-820	2
308	Non-Ischaemic Heart Disease in Diabetes Mellitus. 1992 , 255-265	1
307	Estimation of Exposure to Hazardous Chemicals. 1981 , 323-388	3
306	Complications of Diabetes Mellitus. 2011 , 1462-1551	7
305	Efecto pronóstico diferencial de la diabetes mellitus tipo 2 en mujeres y varones con insuficiencia cardiaca y fracción de eyección conservada. 2020 , 73, 463-470	5
304	Cardiomyopathie Diabétique: une entité spécifique?. 2017 , 201, 325-337	1
303	Management of the Trauma Victim with Pre-Existing Endocrine Disease. 1994 , 10, 537-554	5
302	The effect of diabetes and the common diabetogenic TBC1D4 p.Arg684Ter variant on cardiovascular risk in Inuit in Greenland. 2020 , 10, 22081	3
301	Postprandial increase in glucagon-like peptide-1 is blunted in severe heart failure. 2020 , 134, 1081-1094	3
300	HEREDITARY AND ACQUIRED CARDIOMYOPATHIES IN EXPERIMENTAL ANIMALS: MECHANICAL, BIOCHEMICAL, AND STRUCTURAL FEATURES. 1979 , 317, 59-88	32
299	Cardiovascular disease in diabetes type 2: current concepts. 2018 , 284, 240-253	7
298	Coronary artery disease in IDDM. Gender differences in risk factors but not risk. 1996 , 16, 720-6	101

297	Clinical misconceptions dispelled by epidemiological research. 1995 , 92, 3350-60	49
296	Diabetics with coronary disease have a prevalence of asymptomatic ischemia during exercise treadmill testing and ambulatory ischemia monitoring similar to that of nondiabetic patients. An ACIP database study. ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot Investigators. 1996 , 93, 2097-105	47
295	Metabolic and Molecular Imaging of the Diabetic Cardiomyopathy. 2020 , 126, 1628-1645	14
294	Adipocyte-specific loss of PPAR attenuates cardiac hypertrophy. 2016 , 1, e89908	50
293	The cardiac phenotype induced by PPAR β overexpression mimics that caused by diabetes mellitus. 2002 , 109, 121-130	649
292	Evidence for cardiomyopathy in familial diabetes mellitus. 1977 , 60, 884-99	538
291	Abnormal cardiac function in the streptozotocin-diabetic rat. Changes in active and passive properties of the left ventricle. 1990 , 86, 481-8	101
290	Identification and characterization of a gene regulating enzymatic glycosylation which is induced by diabetes and hyperglycemia specifically in rat cardiac tissue. 1995 , 96, 1759-67	49
289	The cardiac phenotype induced by PPAR α overexpression mimics that caused by diabetes mellitus. 2002 , 109, 121-30	364
288	Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics. <i>Cardiovascular Diabetology</i> , 2020 , 19, 158	8.7 7
287	Diabetes Mellitus and Long-Term Risk for Heart Failure After Coronary Revascularization. 2020 , 84, 471-478	3
286	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes - A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society. 2020 , 85, 82-125	7
285	Elapachone ameliorates lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. 2014 , 9, e91039	8
284	Joint modelling of potentially avoidable hospitalisation for five diseases accounting for spatiotemporal effects: A case study in New South Wales, Australia. 2017 , 12, e0183653	6
283	EVALUATION OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN TYPE II DIABETES MELLITUS □ THE ROLE OF VALSALVA MANEUVER. 2014 , 3, 2898-2906	1
282	Type 2 diabetes mellitus and multiple chronic diseases. 2018 , 21, 455-461	4
281	Is Diabetes Mellitus a Risk Factor for Poor Outcomes after Left Ventricular Assist Device Placement?. 2017 , 44, 115-119	9
280	Clinical Significance of Skin Autofluorescence in Patients With Type 2 Diabetes Mellitus With Chronic Heart Failure. 2018 , 9, 83-89	7

279	Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus. 2020 , 12, 165-171	7
278	4-Nitroquinoline 1-Oxide-Induced Tongue and Esophagus Carcinogenesis in Obese and Diabetic TSOD Mice. 2017 , 8, 97-104	4
277	The Usage of Heart Failure Biomarkers in China. 2017 , 2, 165-170	1
276	Evolution of subclinical myocardial dysfunction detected by two-dimensional and three-dimensional speckle tracking in asymptomatic type 1 diabetic patients: a long-term follow-up study. 2017 , 4, 73-81	10
275	Influence of Race in the Association of Diabetes and Heart Failure. 2018 , 12, 17-21	1
274	IMMUNOREGULATORY IMBALANCE AND FUNCTIONAL STATE OF THE HEART IN THE PATIENTS WITH DIABETES MELLITUS TYPE 2. 2018 , 20, 833-846	4
273	Subcellular microRNAs in diabetic cardiomyopathy. 2020 , 8, 1602	4
272	The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure. 2006 , 2, 139-44	3
271	Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes. 2020 , 26, 5911-5932	1
270	Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. 2019 , 19, 1818-1849	11
269	Macrovascular Complications of Type 2 Diabetes Mellitus. 2020 , 18, 110-116	41
268	Diabetes and Heart Failure: Is it Hyperglycemia or Hyperinsulinemia?. 2020 , 18, 148-157	4
267	Heart failure in South Asia. 2013 , 9, 102-11	49
266	The cholesterol paradox may be attenuated in heart failure patients with diabetes. 2019 , 110, 507-514	1
265	Editorial: Heart Failure in Type 2 Diabetes – The Forgotten Complication. 2018 , 25, 123-130	3
264	Diabetes Mellitus and Cardiovascular Disease in the Elderly. 2008 , 179-214	2
263	Cardiac Outcomes After Myocardial Infarction in Elderly Patients With Diabetes Mellitus. 2002 , 11, 504-519	13
262	Associations among Obesity Degree, Glycemic Status, and Risk of Heart Failure in 9,720,220 Korean Adults. 2020 , 44, 592-601	8

261	Mitochondrial Mechanisms in Diabetic Cardiomyopathy. 2020 , 44, 33-53	35
260	Echocardiographic Parameters as Cardiovascular Mortality Predictors in Chronic Hemodialysis Patients. 2014 , 05, 635-643	2
259	Diabetic Cardiovascular Risk and Carnitine Deficiency & Carnitine Deficiency in Clinical Diabetes Mellitus. 2014 , 04, 202-208	2
258	Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus. 2020 , 11, 150-154	1
257	Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy. 2015 , 6, 943-60	38
256	Mortality and Morbidity in HFEF, HFEF, and HFEF Patients with Diabetes in the Middle East. 2020 , 35, e99	2
255	Myocardial Involvement in Chagas Disease and Insulin Resistance: A Non-Metabolic Model of Cardiomyopathy. 2020 , 15, 36	2
254	Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019. 2019 , 113, 787-891	29
253	Necropsy findings in a cat with diabetes mellitus and heart failure. 2021 , 7, 20551169211055383	
252	Bone Morphogenetic Protein 7 Gene Delivery Improves Cardiac Structure and Function in a Murine Model of Diabetic Cardiomyopathy. 2021 , 12, 719290	3
251	Diabetes With Cardiomyopathy: At the Juncture of Knowledge and Prevention. 2021 , 78, 1599-1602	1
250	The role of hyperglycaemia in the development of diabetic cardiomyopathy. 2021 , 114, 748-760	5
249	Senescence and Type 2 Diabetic Cardiomyopathy: How Young Can You Die of Old Age?. 2021 , 12, 716517	1
248	Disturbed Lipid Metabolism in Diabetic Patients with Manifest Coronary Artery Disease Is Associated with Enhanced Inflammation. 2021 , 18,	1
247	Increased myofilament calcium sensitivity is associated with decreased cardiac troponin I phosphorylation in the diabetic rat heart. 2021 , 106, 2235-2247	0
246	Inhibition of the long non-coding RNA ZFAS1 attenuates ferroptosis by sponging miR-150-5p and activates CCND2 against diabetic cardiomyopathy. 2021 , 25, 9995-10007	7
245	MicroRNA targets and biomarker validation for diabetes-associated cardiac fibrosis. 2021 , 174, 105941	6
244	Dilatative Kardiomyopathie (DCM) Morphologie und Biologie. Myokarditis und DCM. 2000 , 929-1053	

243 Prevention, Diagnosis and Management of Heart Disease in Patients with Renal Failure. **2002**, 129-145

242 Hypertension, Diabetes and the Heart. **2002**, 65-84

241 Pathophysiology and Management of Congestive Heart Failure in Patients with Diabetes Mellitus. **2002**, 211-229

240 [Aging of cardiovascular system and female hormone--heart failure and estrogen]. **2003**, 40, 332-5

239 Epigenetic Alterations in Diabetic Cardiomyopathy. **2003**, 465-479

238 References. **2003**, 97-102

1

237 Dyslipidaemia: implications for cardiovascular risk in hypertensive diabetic subjects. **2003**, 77-96

236 Dilated Cardiomyopathies and Congestive Heart Failure. **2003**, 35-65

235 Metabolic co-morbid conditions in chronic heart failure. **2003**, 35-57

234 Heart Failure in Women. **2004**, 65-91

233 ??????????(4.????????????????/?????,?69????????????). **2006**, 14, 69-73

232 Early Up-Regulation of Multiple Signaling Pathways in Type I Diabetic Cardiomyopathy. **2006**, 6, 812-817

231 The Heart and the Kidney. **2007**, 2819-2837

230 Oedeem, voeten. **2007**, 689-706

229 Acute Coronary Syndrome, Myocardial Infarction, Heart Failure and Stable Coronary Artery Disease Specific Considerations in Diabetes. **2007**, 463-473

228 The Evaluation of Cardiac and Peripheral Arterial Disease in Patients with Diabetes Mellitus. **2007**, 437-461

227 Heart Failure in Women. **2009**, 33-47

226 Heart Failure: From Epidemiology to Pathophysiology. **2009**, 3-11

- 225 Diabetic Cardiomyopathy. **2009**, 33, 9
- 224 Imaging of Myocardial Metabolism. **2010**, 641-656
- 223 Metabolic and Cardiovascular Effects of Exercise in the Adult With Diabetes. **2010**, 1-32
- 222 Congestive Heart Failure. 684-697
- 221 Neuroimaging of Cardiovascular Disease. **2011**, 215-255
- 220 50 Oedeem, voeten. **2011**, 651-666
- 219 Diabetes und Herz. **2011**, 553-557
- 218 The role of brain natriuretic peptide and NT- probrain natriuretic peptide in diagnostics of chronic heart failure and asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus. **2011**, 14, 31-35
- 217 Does impaired glucose tolerance associate with heart failure?. **2012**, 18, 245-251
- 216 Diabetic cardiomyopathy What do we know about it?. **2013**, 03, 26-32 2
- 215 Correlation between plasma proBNP, echocardiographic and clinical parameters in patients with type 2 diabetes mellitus. **2013**, 16, 27-32
- 214 PDE-5 Inhibitors in Protection of Diabetic Heart. **2014**, 323-338
- 213 Cardiac Energy Metabolism in Heart Failure Associated with Obesity and Diabetes. **2014**, 69-88
- 212 ECHOCARDIOGRAPHIC EVALUATION OF DIASTOLIC DYSFUNCTION IN ASYMPTOMATIC TYPE 2 DIABETES MELLITUS PATIENTS. **2014**, 3, 200-209 1
- 211 Hormonal Effects on Cardiac Performance. **1984**, 593-603
- 210 Pathologisch-anatomische Veränderungen am Herzen bei Diabetes mellitus. **1986**, 27-40 1
- 209 Cardiac Dysfunction in the Diabetic Heart. **1987**, 165-176
- 208 Diabetic Cardiomyopathy. **1987**, 442-443

- 207 Risk Factors for Coronary Artery Disease and Atherothrombotic Brain Infarction in the Elderly. **1988**, 393-413
- 206 Diabetic Cardiomyopathy with Special Reference to Hypertension. **1988**, 46-51
- 205 Diabetes und Herz. **1989**, 501-507
- 204 Metabolische Erkrankungen mit vorwiegend restriktiver Funktionsstörung des Myokards. **1989**, 347-359
- 203 Myokardbeteiligung bei weiteren Erkrankungen des Stoffwechsels, der Ernährung, des Endokriniums und des hämatologischen Systems. **1989**, 360-394
- 202 Biochemistry of the Heart. **1990**, 1-71
- 201 Diabetes mellitus. **1991**, 9-43
- 200 Diabetes and Hypertension: A Review. **1991**, 18, 509-524 7
- 199 Electron Microscopic Cytochemical Studies on ATPase and Acid Phosphatase Activities of Cardiac Myocytes in Streptozotocin Induced Diabetic Rats. **1992**, 211-224
- 198 In Vivo ³¹-NMR Spectroscopic Investigation of Myocardial Energy Metabolism in Alloxan-Induced Diabetic Rabbits. **1992**, 237-249
- 197 Epidemiologie. **1992**, 5-11
- 196 The Heart in Diabetic Nephropathy. **1992**, 205-217
- 195 Radionuclide Assessment of Left Ventricular Function in Middle-Aged Asymptomatic Non-Insulin-Dependent Diabetic Patients. **1992**, 21-33
- 194 Diabetes Prolongs the Action Potential Duration in Rat Ventricular Muscle Probably Via Enhanced Calcium Current. **1992**, 155-171
- 193 Usefulness of Exercise Tl-201 Myocardial Scintigraphy to Detect Asymptomatic Heart Disease in Diabetic Patients. **1992**, 35-45
- 192 Increases in Voltage-Sensitive Calcium Channel of Cardiac and Skeletal Muscle in Streptozotocin-Induced Diabetic Rats. **1992**, 173-182
- 191 Biochemical and Morphologic Alterations in Cardiac Myocytes in Streptozotocin-Induced Diabetic Rats. **1992**, 139-153 1
- 190 Changes in Cell Morphology, [Ca²⁺]_i and pHi During Metabolic Inhibition in Isolated Myocytes of Diabetic Rats Using Dual-Loading of Fura-2 and BCECF. **1992**, 183-198

- 189 Diabetische Herzkrankheit. **1993**, 358-369
- 188 Cardiomyopathies. **1994**, 306-335
- 187 Diabetische Herzkrankheit. **1996**, 419-432
- 186 Conclusion. **1996**, 252-259
- 185 Cardiovascular manifestations and complications of diabetes mellitus. **1996**, 419-430
- 184 Diabetes as a Risk Factor for Cardiovascular Disease: Experimental Models. **1996**, 47-75
- 183 Ketone Body Metabolism in the Diabetic Heart. **1996**, 143-165
- 182 Pathologic Alterations of the Heart in Diabetes Mellitus. **1996**, 23-40 1
- 181 Heart disease in patients with the diabetic renal-retinal syndrome: clinical considerations. **1998**, 211-222
- 180 Epidemiologic Insights into Progression from Hypertension to Heart Failure. **1998**, 3-12 1
- 179 Glukosetoleranz und Diabetes mellitus im Alter. **1999**, 203-243
- 178 Diagnostik. **2015**, 31-73
- 177 Diabetes Mellitus and Metabolic Syndrome. **2015**, 55-79
- 176 ECHOCARDIOGRAPHIC EVALUATION OF DIASTOLIC FUNCTION IN ASYMPTOMATIC TYPE 2 DIABETES AND RELATION WITH DURATION OF DM. **2016**, 3, 1170-1173
- 175 New peroral antidiabetic drugs and heart failure. **2016**, 18, 78-82
- 174 Heart failure in diabetes: effects of anti-hyperglycemic drug therapy. **2016**, 19, 229-236 1
- 173 Heart Failure and Chronic Kidney Disease in Type 2 Diabetes. **2016**, 1, 252-258 2
- 172 Heart Failure Prevention. **2017**, 267-284 2

- 171 Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure. **2017**, 21, 618-629 2
- 170 Heart Failure with Normal Left Ventricular Ejection Fraction (HFNEF). **2017**, 273-339
- 169 IS TOBACCO DETRIMENTAL THAN DIABETES?. **2018**, 5, 1221-1225
- 168 Heart failure in diabetes: From an increased risk to a treatment target. **2018**, 21, 399-403 1
- 167 Oxidative Stress and Labile Zinc in Heart Dysfunction Under Hyperglycemia. **2019**, 397-412
- 166 Prognostic role of ST2 in patients with chronic heart failure of ischemic etiology and carbohydrate metabolism disorders. **2019**, 91, 32-37 2
- 165 Heart failure and diabetes mellitus: insight into comorbidity. **2019**, 22, 79-87 1
- 164 Diabetes Mellitus and Chronic Heart Failure. **2019**, 65, 307-313
- 163 GLUT4 expression and glucose transport in human induced pluripotent stem cell-derived cardiomyocytes.
- 162 7. Diabetes and Heart Failure: How to Treat Doubles Dangers. **2019**, 108, 1902-1911
- 161 A modern view on the mechanisms of diabetic cardiomyopathy development and the its modification options. **2019**, 142-147 1
- 160 Analysis of National Health and Insurance Registers for All-Cause Mortality in Patients with Heart Failure with and without Diabetes Mellitus in Poland in 2012. **2019**, 26, e921138
- 159 Relationship of diabetic retinopathy and systemic complications of diabetes. **2020**, 6, 94-98
- 158 Echocardiographic Diagnosis of Diabetic Cardiomyopathy. **2020**, 5, 17-23
- 157 Glucose Fluctuation and Cardiovascular Diseases. **2020**, 61, 633-635
- 156 NAD+ Redox Imbalance in the Heart Exacerbates Diabetic Cardiomyopathy.
- 155 [Subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus]. **2020**, 66, 56-63 1
- 154 Review of Insulin Resistance in Dilated Cardiomyopathy and Implications for the Pediatric Patient Short Title: Insulin Resistance DCM and Pediatrics. **2021**, 9, 756593 0

153	Lifetime Risk of Heart Failure and Trends in Incidence Rates Among Individuals With Type 2 Diabetes Between 1995 and 2018. 2021 , 10, e021230	
152	The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?. 2021 , 1-10	0
151	Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions. 2021 , 1	1
150	Joint influences of obesity, diabetes, and hypertension on indices of ventricular remodeling: Findings from the community-based Framingham Heart Study. 2020 , 15, e0243199	4
149	Have a heart: failure to increase GLP-1 caused by heart failure increases the risk of diabetes. 2020 , 134, 3119-3121	1
148	Heart Failure in Diabetes Mellitus: An Updated Review. 2020 , 26, 5933-5952	1
147	Skin Autofluorescence as a Predictor of First Heart Failure Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction. 2020 , 11, 247-255	2
146	Incidence of Heart Failure among Diabetic Patients with Ischemic Heart Disease: A Cohort Study.	
145	Gender Differences in Cardiac Function Following Three-Month Administration of Tofogliflozin in Patients With Diabetes Mellitus. 2020 , 12, 530-538	2
144	Incidence of Heart Failure among Diabetic Patients with Ischemic Heart Disease: A Cohort Study.	
143	Myokardinfarkt: Klinik und Diagnostik. 2005 , 230-251	
142	Heart failure, diabetes and the thiazolidinediones: an unfolding story. 2005 , 2, 159-161	
141	Diabetes und Herz. 2009 , 525-528	
140	Molecular pathogenesis of heart failure in diabetes mellitus [new direction for the therapeutic approach. 2020 , 74, 452-463	1
139	Diabetic cardiomyopathy: definition, diagnosis criteria, treatment directions and prevention of heart failure. 2020 , 1, 93-101	
138	Pulmonary Manifestations of Endocrine and Metabolic Disorders. 1989 , 10, 645-653	13
137	SGLT-2i and Cardiovascular Prognosis. 2020 , 26, 3905-3907	0
136	The heart in diabetes. 1984 , 140, 583-93	11

135	Cardiomyopathy in diabetic patients. 1984 , 140, 610-2	1
134	Cardiac pathology in the hypertensive diabetic rat. Biventricular damage with right ventricular predominance. 1989 , 134, 1159-66	19
133	Hypertensive-diabetic cardiomyopathy in the rat: an experimental model of human disease. 1981 , 102, 219-28	104
132	Diabetic hearts and biguanides. 1975 , 113, 175-6	
131	A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus. 2009 , 34, 368-78	2
130	Histological changes in the heart and the proximal aorta in experimental diabetic rats fed with Piper sarmentsoum. 2012 , 9, 396-404	13
129	Prevalence of systemic co-morbidities in patients with various grades of diabetic retinopathy. 2014 , 140, 77-83	9
128	Diabetes mellitus and burns. Part I-basic science and implications for management. 2015 , 5, 1-12	7
127	Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure. 2016 , 8, 2450-8	13
126	3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy. 2020 , 8, 1345	2
125	Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets. 2020 , 3, 82-97	2
124	Sleeve Gastrectomy Ameliorates Diabetes-Induced Cardiac Hypertrophy Correlates With the MAPK Signaling Pathway. <i>Frontiers in Physiology</i> , 2021 , 12, 785799	4.6 1
123	MiR 208a Regulates Mitochondrial Biogenesis in Metabolically Challenged Cardiomyocytes. 2021 , 10,	0
122	Heart Failure with Reduced Ejection Fraction-Does Sex Matter?. 2021 , 18, 345-352	1
121	Changes in Cardiac Metabolism in Prediabetes. 2021 , 11,	1
120	The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity. 2021 , 10,	3
119	Risk prediction of chronic heart failure in patients with type 2 diabetes. 2021 , 7, 19-27	
118	Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants.. 2022 , 1	4

117	Cardiovascular Burden Is High in Pediatric Lung Transplant Recipients.. 2022 ,		0
116	3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy. 2020 , 8, 1345-1345		2
115	Natural AMPK Activators in Cardiovascular Disease Prevention.. 2021 , 12, 738420		1
114	Identification of Silent Myocardial Ischemia in Patients with Long-Term Type 1 and Type 2 Diabetes.. 2022 , 19,		
113	Transforming growth factor- β in myocardial disease.. 2022 ,		11
112	Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors.. 2022 , 13, 241		0
111	Diabetes and prediabetes in patients with heart failure and preserved ejection fraction.. 2021 ,		3
110	Glycemic Markers and Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA).. 2022 ,		3
109	The burden of cardiovascular outcomes in heart failure patients with new-onset, prevalent, and without type 2 diabetes.. 2022 , 111, 460		
108	Ca mishandling and mitochondrial dysfunction: a converging road to prediabetic and diabetic cardiomyopathy.. 2022 , 474, 33		1
107	Outcomes of Patients With Diabetes Versus Patients Without Diabetes Hospitalized With Acute Heart Failure.. <i>American Journal of Cardiology</i> , 2021 ,	3	
106	Prognostic Value of the Acute-to-Chronic Glycemic Ratio at Admission in Heart Failure: A Prospective Study.. 2021 , 11,		0
105	Molecular Mechanisms and Epigenetic Regulation in Diabetic Cardiomyopathy.. 2021 , 8, 725532		0
104	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.. <i>Diabetes Care</i> , 2022 , 45, S144-S174	14.6	46
103	Role of inflammation in diabetic cardiomyopathy.. 2022 , 13, 20420188221083530		2
102	Automatic Microaneurysms Detection for Early Diagnosis of Diabetic Retinopathy Using Improved Discrete Particle Swarm Optimization.. 2022 , 12,		2
101	MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 31	8.7	3
100	Role of Primary Care Clinicians in the Management of Patients With Type 2 Diabetes and Cardiorenal Diseases.		

99	The multifaceted role of cytochrome P450-Derived arachidonic acid metabolites in diabetes and diabetic cardiomyopathy.. 2022 , 1-20	0
98	The impact of lifestyle intervention on left atrial function in type 2 diabetes: results from the DIASTOLIC study.. 2022 , 1	
97	Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications.. 2022 , 10,	0
96	Effect of Metformin on T2D-Induced MAM Ca Uncoupling and Contractile Dysfunction in an Early Mouse Model of Diabetic HFpEF.. 2022 , 23,	0
95	Current challenges in the treatment of cardiac fibrosis: recent insights into the sex-specific differences of glucose-lowering therapies on the diabetic heart: IUPHAR Review 33.. 2022 ,	0
94	The impact of type-2 diabetes mellitus on cardiac rehabilitation outcomes: a meta-analysis.. 2022 ,	
93	Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus.. 2022 , 23,	3
92	Multiparametric CMR imaging of myocardial structure and function changes in diabetic mini-pigs with preserved LV function: a preliminary study.. 2022 , 22, 143	0
91	Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy.. 2022 ,	0
90	EVALUATION OF CARDIAC SYSTOLIC FUNCTION IN ASYMPTOMATIC DIABETES PATIENTS AND ITS CORRELATION WITH DURATION OF DIABETES. 2021 , 87-89	
89	Cardiac Metabolism and Contractile Function in Mice with Reduced Trans-Endothelial Fatty Acid Transport.. 2021 , 11,	1
88	Predictors of Epicardial Fat Volume Decrease after Dapagliflozin Treatment in Patients with Type 2 Diabetes.. 2021 , 58,	
87	Myocardial Extracellular Volume Fraction and T1 Mapping by Cardiac Magnetic Resonance Compared Between Patients With and Without Type 2 Diabetes, and the Effect of ECV and T2D on Cardiovascular Outcomes.. 2021 , 8, 771363	1
86	Regulating Polyamine Metabolism by miRNAs in Diabetic Cardiomyopathy.. 2021 , 21, 52	0
85	Empagliflozin: a path from glycemic control to reduced cardiovascular mortality and heart failure-related hospitalizations. 2022 , 26, 4807	
84	Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies.. 2022 ,	8
83	The Role of Mitochondrial Biogenesis Dysfunction in Diabetic Cardiomyopathy.. 2022 ,	0
82	Recent Experimental Studies of Maternal Obesity, Diabetes during Pregnancy and the Developmental Origins of Cardiovascular Disease.. 2022 , 23,	3

81	Sex and Gender-Related Issues in Heart Failure.. 2022 , 40, 259-268		
80	Image_1.tif. 2018 ,		
79	Table_1.DOC. 2018 ,		
78	Table_2.DOC. 2018 ,		
77	Presentation_1.PPTX. 2019 ,		
76	Editorial: Translational Approaches for Targeting Cardiovascular Complications of Diabetes. 2021 , 12, 799020		
75	Ketogenic Diet and Cardiac Substrate Metabolism.. 2022 , 14,		1
74	Insulin Therapy is Associated With Increased Myocardial Interstitial Fibrosis and Cardiomyocyte Apoptosis in a Rodent Model of Experimental Diabetes.. <i>Frontiers in Physiology</i> , 2022 , 13, 890907	4.6	0
73	Clinical and echocardiographic characteristics in patients with heart failure and type 2 diabetes.. 2022 ,		
72	20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units. 2022 , 9, 149		1
71	Diabetic cardiomyopathy and inflammation: development of hostile microenvironment resulting in cardiac damage. 2022 , 70,		1
70	Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence.. 2022 , 1		2
69	Women with type 2 diabetes and coronary artery disease have a higher risk of heart failure than men, with a significant gender interaction between heart failure risk and risk factor management: a retrospective registry study.. 2022 , 10,		0
68	Roflumilast-Mediated Phosphodiesterase 4D Inhibition Reverses Diabetes-Associated Cardiac Dysfunction and Remodeling: Effects Beyond Glucose Lowering.		0
67	Biochemical mechanism underlying the pathogenesis of diabetic retinopathy and other diabetic complications in humans: the methanol-formaldehyde-formic acid hypothesis. 2022 , 54, 415-451		
66	Dicarbonyl Stress in Diabetic Vascular Disease. 2022 , 23, 6186		0
65	Glucose dysregulation and repolarization variability markers are short-term mortality predictors in decompensated heart failure. 2022 , 11,		1
64	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. <i>Diabetes Care</i> ,	14.6	8

63	Glucose dysregulation and subclinical cardiac dysfunction in older adults: The Cardiovascular Health Study. <i>Cardiovascular Diabetology</i> , 2022 , 21,	8.7	
62	Signaling Pathways Related to Oxidative Stress in Diabetic Cardiomyopathy. <i>Frontiers in Endocrinology</i> , 13,	5.7	1
61	The Role of Mitochondria in Metabolic Syndrome-Associated Cardiomyopathy. <i>Oxidative Medicine and Cellular Longevity</i> , 2022 , 2022, 1-17	6.7	0
60	Insulinotropic Effects of Nephilysin and/or Angiotensin Receptor Inhibition in Mice. <i>Frontiers in Endocrinology</i> , 13,	5.7	
59	Targeting cholesteryl ester accumulation in the heart improves cardiac insulin response. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 152, 113270	7.5	0
58	Elapachone, an NQO1 activator, alleviates diabetic cardiomyopathy by regulating antioxidant ability and mitochondrial function. <i>Phytomedicine</i> , 2022 , 104, 154255	6.5	0
57	Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. 2022 , 18, 10		1
56	Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Physiology</i> , 13,	4.6	1
55	Exosomal microRNAs in diabetic heart disease. <i>Cardiovascular Diabetology</i> , 2022 , 21,	8.7	0
54	Glycemic status and the association of change in blood pressure with incident cardiovascular disease. 2022 ,		
53	Gut microbiota: A new therapeutic target for diabetic cardiomyopathy. 13,		0
52	Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism.		0
51	The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective. 2022 , 14, 1730		3
50	Heterocyclic compounds as a magic bullet for diabetes mellitus: a review. 2022 , 12, 22951-22973		1
49	Acute effects of euglycemic-hyperinsulinemia on myocardial contractility in male mice. 2022 , 10,		0
48	Cathepsin B deteriorates diabetic cardiomyopathy induced by streptozotocin via promoting NLRP3 mediated pyroptosis. 2022 ,		1
47	123I-MIBG imaging in heart failure: impact of comorbidities on cardiac sympathetic innervation.		0
46	The need for adjusting experimental models to meet clinical reality.		0

45	HbA1c level is associated with the development of heart failure with recovered ejection fraction in hospitalized heart failure patients with type 2 diabetes. 2022,	0
44	The role of microRNAs in the pathophysiology, diagnosis, and treatment of diabetic cardiomyopathy.	1
43	Current Status of Dapagliflozin in Congestive Heart Failure. 2022,	0
42	Diabetes and cardiovascular risk according to gender: an overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials. 2022,	0
41	Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy. 9,	0
40	Exosomes derived from human umbilical cord mesenchymal stem cells (HUCMSC-EXO) regulate autophagy through AMPK-ULK1 signaling pathway to ameliorate diabetic cardiomyopathy. 2022,	0
39	Early Diabetic Retinopathy Detection Using Elevated Continuous Particle Swarm Optimization Clustering With Raspberry PI. 2022, 15-33	0
38	Mitochondrial quality control mechanisms as molecular targets in diabetic heart. 2022, 137, 155313	0
37	Diabetes Mellitus and Heart Failure. 2022, 12, 1698	0
36	Research status and trends of the diabetic cardiomyopathy in the past 10 years (2012-2021): A bibliometric analysis. 9,	0
35	Exercise-Induced Anti-Senescence and Autophagy Restoration Mitigate Metabolic Disorder-Induced Cardiac Disruption in Mice. Publish Ahead of Print,	0
34	Blockage of MyD88 in cardiomyocytes alleviates cardiac inflammation and cardiomyopathy in experimental diabetic mice. 2022, 206, 115292	1
33	Fibronectin improves the impaired calcium signaling and myofilament activation in diabetic cardiomyocytes.	0
32	Diabetic cardiomyopathy: a brief summary on lipid toxicity.	1
31	Energy substrate metabolism and oxidative stress in metabolic cardiomyopathy.	1
30	Sex differences in heart failure with preserved ejection fraction: From traditional risk factors to sex-specific risk factors. 2022, 18, 174550572211402	0
29	The prognostic impact of magnesium in acute heart failure is different according to the presence of diabetes mellitus. 2022, 7, e197	0
28	Microvascular Disease and the Pathogenesis of Heart Failure in Diabetes: A Tiny Piece of the Tricky Puzzle. 2022, 45, 2817-2819	0

27	Association of biomarkers and risk scores with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. 2022 , 21,	0
26	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes 2023 . 2023 , 46, S158-S190	7
25	The Heart in Diabetic Hypertensive Patients. 2023 , 195-215	0
24	Low stress hyperglycemia ratio predicts worse prognosis in diabetic acute heart failure patients. 2023 ,	0
23	Diabetic microvascular complications predicts non-heart failure with reduced ejection fraction in type 2 diabetes.	0
22	Obesity Paradox among Heart Failure with Reduced Ejection Fraction Patients: A Retrospective Cohort Study. 2023 , 59, 60	0
21	Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study. 2023 , 100692	0
20	Cardiovascular complications in a diabetes prediction model using machine learning: a systematic review. 2023 , 22,	0
19	C1q and Tumor Necrosis Factor Related Protein 9 Protects from Diabetic Cardiomyopathy by Alleviating Cardiac Insulin Resistance and Inflammation. 2023 , 12, 443	0
18	Diagnostic and prognostic biomarkers reflective of cardiac remodelling in diabetes mellitus: A scoping review. 2023 , 40,	0
17	Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. 2023 , 11, 662	0
16	Management of diabetes: Current concepts. 14, 396-411	0
15	Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective. 2023 , 1869, 166714	0
14	Type 2 diabetes and cardiorenal syndromes. A nationwide French hospital cohort study. 2023 , 49, 101441	0
13	Inflammation, dysregulated iron metabolism, and cardiovascular disease. 4,	0
12	Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors. 2023 , 13, 497	1
11	The interplay of inflammation, exosomes and Ca ²⁺ dynamics in diabetic cardiomyopathy. 2023 , 22,	0
10	Is non-alcoholic fatty liver disease a sign of left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus? A systematic review and meta-analysis. 2023 , 11, e003198	0

- 9 Combination of Empagliflozin and Liraglutide protects heart against isoproterenol-induced myocardial infarction in rats. **2023**, 70, 171-180 ○
- 8 Retinol dehydrogenase 10 reduction mediated retinol metabolism disorder promotes diabetic cardiomyopathy in male mice. **2023**, 14, ○
- 7 Potential clinical biomarkers and perspectives in diabetic cardiomyopathy. **2023**, 15, ○
- 6 The joint association of diabetes status and NT-ProBNP with adverse cardiac outcomes in patients with non-ST-segment elevation acute coronary syndrome: a prospective cohort study. **2023**, 22, ○
- 5 Diabetes Induces Cardiac Fibroblast Activation, Promoting a Matrix-Preserving Nonmyofibroblast Phenotype, Without Stimulating Pericyte to Fibroblast Conversion. ○
- 4 Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP. Volume 17, 791-806 ○
- 3 Differential changes in cyclic adenosine 3'-5' monophosphate (cAMP) effectors and major Ca²⁺ handling proteins during diabetic cardiomyopathy. ○
- 2 Central role of cardiac fibroblasts in myocardial fibrosis of diabetic cardiomyopathy. 14, ○
- 1 Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. **2023**, 13, 1024 ○